WO2011026200A2 - Nouveaux procédés permettant de diagnostiquer des maladies auto-immunes - Google Patents
Nouveaux procédés permettant de diagnostiquer des maladies auto-immunes Download PDFInfo
- Publication number
- WO2011026200A2 WO2011026200A2 PCT/BE2010/000061 BE2010000061W WO2011026200A2 WO 2011026200 A2 WO2011026200 A2 WO 2011026200A2 BE 2010000061 W BE2010000061 W BE 2010000061W WO 2011026200 A2 WO2011026200 A2 WO 2011026200A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hnrnp
- antibodies
- syndrome
- sjogren
- patients
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 186
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 94
- 208000021386 Sjogren Syndrome Diseases 0.000 claims abstract description 201
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims abstract description 182
- 201000001981 dermatomyositis Diseases 0.000 claims abstract description 179
- 108010019372 Heterogeneous-Nuclear Ribonucleoproteins Proteins 0.000 claims description 244
- 102000006479 Heterogeneous-Nuclear Ribonucleoproteins Human genes 0.000 claims description 238
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 186
- 108010052492 Heterogeneous-Nuclear Ribonucleoprotein Group F-H Proteins 0.000 claims description 170
- 102000018753 Heterogeneous-Nuclear Ribonucleoprotein Group F-H Human genes 0.000 claims description 131
- 239000000427 antigen Substances 0.000 claims description 127
- 102000036639 antigens Human genes 0.000 claims description 115
- 108091007433 antigens Proteins 0.000 claims description 115
- 108010025934 hnRNP A2 Proteins 0.000 claims description 97
- 101710089655 Poly(rC)-binding protein 1 Proteins 0.000 claims description 92
- 239000012634 fragment Substances 0.000 claims description 90
- 102100034960 Poly(rC)-binding protein 1 Human genes 0.000 claims description 73
- 239000012472 biological sample Substances 0.000 claims description 68
- 210000002966 serum Anatomy 0.000 claims description 68
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 claims description 65
- 238000001262 western blot Methods 0.000 claims description 64
- 238000012360 testing method Methods 0.000 claims description 62
- 238000004458 analytical method Methods 0.000 claims description 60
- 238000002965 ELISA Methods 0.000 claims description 44
- 238000003556 assay Methods 0.000 claims description 42
- 239000000523 sample Substances 0.000 claims description 42
- 238000003018 immunoassay Methods 0.000 claims description 38
- 210000004369 blood Anatomy 0.000 claims description 33
- 239000008280 blood Substances 0.000 claims description 33
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 28
- 239000011324 bead Substances 0.000 claims description 24
- 239000007790 solid phase Substances 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 18
- 238000009739 binding Methods 0.000 claims description 18
- 108010084680 Heterogeneous-Nuclear Ribonucleoprotein K Proteins 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 16
- 238000003127 radioimmunoassay Methods 0.000 claims description 16
- 102000005646 Heterogeneous-Nuclear Ribonucleoprotein K Human genes 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 238000002372 labelling Methods 0.000 claims description 14
- 108090000292 RNA-binding protein FUS Proteins 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 210000003296 saliva Anatomy 0.000 claims description 12
- 102000003890 RNA-binding protein FUS Human genes 0.000 claims description 10
- 210000002381 plasma Anatomy 0.000 claims description 10
- 210000001138 tear Anatomy 0.000 claims description 10
- 210000003097 mucus Anatomy 0.000 claims description 8
- -1 hnRNP-BI Proteins 0.000 claims description 7
- 206010003445 Ascites Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000004043 responsiveness Effects 0.000 claims description 4
- 102000017013 Heterogeneous Nuclear Ribonucleoprotein A1 Human genes 0.000 claims 6
- 241001203952 Feia Species 0.000 claims 4
- 239000000203 mixture Substances 0.000 abstract description 16
- 102000004389 Ribonucleoproteins Human genes 0.000 abstract description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 abstract description 2
- 208000005987 polymyositis Diseases 0.000 description 130
- 108090000623 proteins and genes Proteins 0.000 description 126
- 208000018631 connective tissue disease Diseases 0.000 description 91
- 230000001363 autoimmune Effects 0.000 description 84
- 102000004169 proteins and genes Human genes 0.000 description 84
- 206010039073 rheumatoid arthritis Diseases 0.000 description 82
- 235000018102 proteins Nutrition 0.000 description 80
- 201000003068 rheumatic fever Diseases 0.000 description 78
- 230000009257 reactivity Effects 0.000 description 72
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 67
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 66
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 66
- 201000010099 disease Diseases 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 58
- 208000034943 Primary Sjögren syndrome Diseases 0.000 description 56
- 206010039710 Scleroderma Diseases 0.000 description 52
- 102100035621 Heterogeneous nuclear ribonucleoprotein A1 Human genes 0.000 description 51
- 201000009594 Systemic Scleroderma Diseases 0.000 description 50
- 206010042953 Systemic sclerosis Diseases 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 32
- 150000001413 amino acids Chemical class 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 28
- 239000000758 substrate Substances 0.000 description 28
- 238000001514 detection method Methods 0.000 description 26
- 239000003112 inhibitor Substances 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 22
- 238000011282 treatment Methods 0.000 description 22
- 239000012528 membrane Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 238000005406 washing Methods 0.000 description 16
- 238000007792 addition Methods 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 238000003745 diagnosis Methods 0.000 description 14
- 239000003550 marker Substances 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 208000025747 Rheumatic disease Diseases 0.000 description 12
- 238000012545 processing Methods 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 230000009885 systemic effect Effects 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 230000004075 alteration Effects 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 238000007619 statistical method Methods 0.000 description 10
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 230000007170 pathology Effects 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 241001523209 Antissa Species 0.000 description 6
- 102100029968 Calreticulin Human genes 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 241000283707 Capra Species 0.000 description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 102000019040 Nuclear Antigens Human genes 0.000 description 6
- 108010051791 Nuclear Antigens Proteins 0.000 description 6
- 108010033276 Peptide Fragments Proteins 0.000 description 6
- 102000007079 Peptide Fragments Human genes 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 6
- 101100473045 Rattus norvegicus Hnrnpa2b1 gene Proteins 0.000 description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000001120 cytoprotective effect Effects 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 238000001502 gel electrophoresis Methods 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 238000000074 matrix-assisted laser desorption--ionisation tandem time-of-flight detection Methods 0.000 description 6
- 201000006417 multiple sclerosis Diseases 0.000 description 6
- 206010028417 myasthenia gravis Diseases 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 206010043778 thyroiditis Diseases 0.000 description 6
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 6
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- KJDSORYAHBAGPP-UHFFFAOYSA-N 4-(3,4-diaminophenyl)benzene-1,2-diamine;hydron;tetrachloride Chemical compound Cl.Cl.Cl.Cl.C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 KJDSORYAHBAGPP-UHFFFAOYSA-N 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000045500 Diseae Species 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 206010013774 Dry eye Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 101001017544 Homo sapiens Heterogeneous nuclear ribonucleoprotein F Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 102100024939 RNA-binding motif protein, X chromosome Human genes 0.000 description 4
- 101710176041 RNA-binding motif protein, X chromosome Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000006472 autoimmune response Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000000326 densiometry Methods 0.000 description 4
- 230000006866 deterioration Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 208000007475 hemolytic anemia Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000099 in vitro assay Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101710117545 C protein Proteins 0.000 description 2
- 108010009685 Cholinergic Receptors Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- 102100028818 Heterogeneous nuclear ribonucleoprotein L Human genes 0.000 description 2
- 102100023999 Heterogeneous nuclear ribonucleoprotein R Human genes 0.000 description 2
- 108010084674 Heterogeneous-Nuclear Ribonucleoprotein L Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000854014 Homo sapiens Heterogeneous nuclear ribonucleoprotein A1 Proteins 0.000 description 2
- 101001047853 Homo sapiens Heterogeneous nuclear ribonucleoprotein R Proteins 0.000 description 2
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 description 2
- 208000019758 Hypergammaglobulinemia Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 2
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102100022742 Lupus La protein Human genes 0.000 description 2
- 206010050551 Lupus-like syndrome Diseases 0.000 description 2
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108010047956 Nucleosomes Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102100033073 Polypyrimidine tract-binding protein 1 Human genes 0.000 description 2
- 101710132817 Polypyrimidine tract-binding protein 1 Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108091030084 RNA-OUT Proteins 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 description 2
- 101100306832 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RRM3 gene Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000473945 Theria <moth genus> Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 102000034337 acetylcholine receptors Human genes 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 238000002669 amniocentesis Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 230000003460 anti-nuclear Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000002230 centromere Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000012953 feeding on blood of other organism Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000005021 gait Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000010820 immunofluorescence microscopy Methods 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000010324 immunological assay Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 239000003547 immunosorbent Substances 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 210000004561 lacrimal apparatus Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 239000002923 metal particle Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 238000001821 nucleic acid purification Methods 0.000 description 2
- 210000001623 nucleosome Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000164 protein isolation Methods 0.000 description 2
- 230000009145 protein modification Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002901 radioactive waste Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 210000001324 spliceosome Anatomy 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 208000011834 subacute cutaneous lupus erythematosus Diseases 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 108010042923 Heterogeneous-Nuclear Ribonucleoprotein Group M Proteins 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229920000131 polyvinylidene Polymers 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
Definitions
- the present invention relates to new methods of diagnosing several autoimmune diseases. More particularly the present invention relates to methods and compositions for detecting anti-heterogeneous nuclear ribonudeoprotein autoantibodies for diagnosing these autoimmune diseases. More in particular, the present invention relates to methods and compositions for detecting anti- heterogeneous nuclear ribonucleoproteins-EI, -F, -H1, -Al, and -B.1, including any combinations of these, for diagnosing autoimmune diseases, more in particular for diagnosing Sjogren's syndrome, mixed connective tissue disease (MCTD) and dermatomyositis (DM).
- MCTD mixed connective tissue disease
- DM dermatomyositis
- Autoantibodies to intracellular antigens are a common feature of systemic autoimmune disorders such as systemic lupus erythematosus (SLE), systemic sclerosis (Ssc), polymyositis (PM), mixed connective tissue disease (MCTD), dermatomyositis (DM), primary Sjogren's syndrome (SSp) or rheumatic arthritis (RA).
- SLE systemic lupus erythematosus
- Ssc systemic sclerosis
- PM polymyositis
- MCTD mixed connective tissue disease
- DM dermatomyositis
- SSp primary Sjogren's syndrome
- RA rheumatic arthritis
- These autoantibodies are typically directed to sets of proteins associated with discrete supramolecular entities built up of either DNA or RNA and proteins, such as the nucleosome, the centromere, the spliceosome, the ribosome or other RNPs.
- HnRNPs comprise a group of approximately 30 different proteins. They mainly play a role in processing of precursor mRNA, but are also involved in telomeric DNA synthesis and cellular apoptotic processes. HnRNPs are composed of at least 1 RNA recognition motif. HnRNP proteins appear to be an important target of autoimmune responses. Several different hnRNP proteins have been described as autoantigens in autoimmune connective tissue diseases.
- hnRNP A1 Autoantibodies to hnRNP A1 were first detected by Jensen ef al. in 63 out of 160 SLE patients (37%) and in 17 out of 71 RA patients (24 %), but only in 1 out of 24 polymyositis patients and in 7 out of 98 healthy controls.
- Anti-hnRNP A2 antibodies target the 36 kDa hnRNP A2 as well as its alternatively spliced variants hnRNP B1 (37 kDa) en B2 (38 kDa). These 3 autoantigens may be designated as the "RA33 complex", that shows reactivity with autoantibodies in 35% of RA patients.
- HnRNP D was identified by Skriner et al. as a new autoantigen in patients with SLE and related disorders.
- Antibodies to hnRNP R were found in 1998 by Hassfeld et a/, in 1 patient with vage aufo-immuun complaints. In 2007 Siapka et at. Found high antibody titers against hnRNP L in patients with systemic sclerosis.
- hnRNP H1 was described as a newly recognized target of autoantibodies. These antibodies were mainly found in patients with Sjogren's syndrome, but were also present in patients with other autoimmune-mediated diseases (WO2009055880).
- Sjogren's syndrome is an autoimmune exocrinopathy, characterized by dryness of the mouth and eyes resulting from a chronic loss of secretory function of the salivary and lacrimal glands.
- Extraglandular systemic manifestations are common and include abnormalities of skin, arthralgia, myalgia, thyroiditis, and pulmonary, renal, gastrointestinal, hematological, cardiac, and neurological abnormalities.
- the etiology of the disease remains unclear. The prevalence of the disease is estimated to be 0.5% and there is a female preponderance.
- Pathological findings involve focal lymphocytic infiltration of affected tissues.
- Anti-SSA antibodies are found in 45-90% of the patients with Sjogren's syndrome.
- Anti-SSB antibodies are found slightly less commonly.
- Anti-SSA antibodies are not specific for Sjogren syndrome as they are found in other systemic diseases such as systemic lupus erythematosus, subacute cutaneous lupus erythematosus and neonatal lupus.
- Sjogren's syndrome can occur in two forms: primary Sjogren's syndrome (not associated with other autoimmune diseases) and secondary Sjogren's syndrome (associated with other autoimmune diseases). Because of the non-specific symptoms (dry eyes and mouth), establishment of the diagnosis of Sjogren's syndrome may be difficult. There is an unmet need for additional accurate and valid diagnostic markers. A number of new autoantigens have recently been suggested: a-fodrin, muscarinic M3 acetylcholine receptor, SS-56, which is structurally related to the 52 kDa SSA antigen, and hnRNP H1.
- hnRNPs as a new targets of autoantibodies in patients with autoimmune diseases.
- hnRNPs are selected from the group consisting of hnRNP-A1 , hnRNP-B1, hnRNP-C1, hnRNP-E1 , hnRNP-F, hnRNP-HI, hnRNP-l, hnRNP-K, and hnRNP-P2.
- the hnRNPs as targets of antibodies in Sjogren's syndrome are one or more hnRNPs selected from the group consisting of hnRNP-A1 , hnRNP-B1, hnRNP-C1, hnRNP-E1, hnRNP-F, hnRNP-l, hnRNP-K, and hnRNP- P2.
- the one or more hnRNPs from said group can be combined with hnRNP-H1 as combined markers for Sjogren's syndrome.
- the present invention identifies hnRNP-F; hnRNP-E1; and the combination of hnRNP-F and hnRNP-E1 as very valuable diagnostic markers and marker-combinations in Sjogren's syndrome.
- the present invention also identifies the following combination of antibodies as very valuable diagnostic combination markers in Sjogren's syndrome: hnRNP-F and hnRNP-H1; hnRNP-E1 and hnRNP-H1; and the combination of hnRNP-F, -E1 , and -H1 ; and the combination of hnRNP-B1, -F, and -E1; and the combination of hnRNP-B1, -F, -E1, and -H1.
- the present invention also identifies additional antibody markers (for example hnRNP-A1) which in combination with any of the above mentioned 4 diagnostic antibody markers and their combinations (hnRNP-E1, -F, -H1 and -B1) that are useful diagnostic antibody marker combinations in Sjogren's syndrome (examples are the combination of hnRNP-A1, -B1, and -F; the combination of hnRNP-AI, -B1, -F, and -E1; the combination of hnRNP-AI, -B1, -F, and -H1; and the combination of hnRNP-AI, -B1, -F. -E1, and -H1).
- additional antibody markers for example hnRNP-A1 which in combination with any of the above mentioned 4 diagnostic antibody markers and their combinations (hnRNP-E1, -F, -H1 and -B1) that are useful diagnostic antibody marker combinations in Sjogren's syndrome (examples are the combination of h
- markers and markercombinations that are also valuable diagnostic markers arid marker-combinations for other autoimmune diseases, more in particular the hnRNP-F; hnRNP-E1; and the combination of hnRNP-F and hnRNP-E1 markers (including the combinations of these markers with the markers hnRNP-H1 and/or hnRNP-B1, example given hnRNP-E1 and hnRNP-H1; hnRNP-F and hnRNP-H1; hnRNP-F, -E1, and -H1; hnRNP-EI , -F, and -B1; and hnRNP-E1, -F, -H1 and -B1,) are useful markers for mixed connective tissue disease, systemic lupus erythematosus, and dermatomyositis.
- the present invention provides for a method for diagnosing Sjogren's syndrome. More particularly the present invention provides methods and compositions for detecting the above mentioned anti-hnRNP autoantibodies for diagnosing Sjogren's syndrome.
- the method of this invention is applicable to a large group of patients, including patients having Sjogren's syndrome, patients being suspected as having Sjogren's syndrome or at risk of developing Sjogren's syndrome, or patients suffering from other autoimmune diseases.
- One aspect of the present invention relates to a method of diagnosing an autoimmune disease, more particularly Sjogren's syndrome, characterized in that the presence of autoantibodies against the above mentioned hnRNPs and the above mentioned combinations is determined in an isolated biological sample derived from a subject.
- the present invention relates to methods of diagnosing autoimmune diseases, more in particular Sjogren's syndrome, by measuring the presence of autoantibodies against the above mentioned hnRNPs and the above mentioned combinations in an isolated biological sample derived from a subject, and wherein the presence of the above mentioned hnRNPs or the above mentioned combinations is indicative for the diagnosis of said autoimmunedisease for said subject, or wherein the presence of the above mentioned hnRNPs or the above mentioned combinations is indicative for the predisposition of said subject to develop said autoimmunedisease.
- the present invention further relates to a method for detecting the above mentioned hnRNP antibodies and the above mentioned combinations in an isolated biological sample, the method comprising the steps of (a) obtaining an isolated biological sample from a patient; and (b) analyzing said isolated biological sample for the presence of antibodies against said hnRNPs.
- said method is characterized in that the corresponding hnRNP proteins, peptides, variants or fragments thereof are used for determining the presence of the above mentioned hnRNP antibodies and the above mentioned combinations.
- said method is characterized in that a hnRNP antigen, more specific an immobilized hnRNP antigen is used for determining the presence of the corresponding hnRNP antibodies.
- said analysis or determination of the presence of autoantibodies against the hnRNPs of this invention is performed in an immunoassay.
- said immunoassay is selected from the group consisting of ELISA, FEIA, western blot, dot blot, bead-based assay, antigen array and Radio Immuno Assay.
- the methods of the invention are used for predicting responsiveness to a medicament.
- Another aspect of the present invention relates to the use of hnRNP proteins of this invention (including the above mentioned hnRNPs and the above mentioned combinations), peptides, variants or fragments thereof to detect the presence of autoantibodies against said hnRNPs in an isolated biological sample derived from a subject.
- the present invention further relates to the use of said hnRNP proteins, peptides, variants or fragments thereof to detect the presence of autoantibodies against said hnRNPs in an isolated biological sample derived from a patient for diagnosing an autoimmune disease, more particularly Sjogren's syndrome.
- the isolated biological sample is a fluid selected from the group consisting of blood, serum, plasma, saliva, tears, mucus and ascites fluid; and preferentially said biological sample is serum.
- said isolated biological sample is derived from blood, plasma, serum, saliva, tears, lymph, urine, cerebrospinal fluid, any biopsy material or tissue sample, including bone marrow, lymph nodes, nervous tissue, skin, hair, fetal material including amniocentesis material, uterine tissue, faeces or semen.
- said isolated biological sample is an antibody-containing isolated biological sample.
- test kit for detecting the presence of antibodies against the hnRNPs of this invention (including the above mentioned hnRNPs and the above mentioned combinations) in an isolated biological sample.
- the test kit additionally comprises a solid phase onto which said antigen is or can be bound.
- the test kit additionally comprises a labeling group which is bound to said antigen or can be bound thereto.
- the test kit additionally comprises at least one other antibody class-specific test reagent.
- the test kit may additionally comprise other conventional reagents such as buffers, substrates and wetting solutions.
- the present invention further relates to the use of said test kit for carrying out any of the methods of the invention.
- Another aspect of the present invention relates to a method of treating an autoimmune disease, more particularly Sjogren's syndrome, comprising administering to a patient an inhibitor that specifically binds to the hnRNP autoantibodies of said patient, in an amount effective to treat the autoimmune disease, more particularly Sjogren's syndrome.
- said inhibitor is selected from the group consisting of hnRNP-E1 and hnRNP-F proteins, peptides, variants, fragments, epitopes, or combinations thereof and an antibody, in particular an antibody that recognizes and inhibits said autoantibodies.
- the present invention further relates to the use of a compound which specifically binds to at least one group of hnRNP autoantibodies or the combination of certain autoantibodies (as described herein above) for the production of a medicine.
- said medicine is used for the treatment of an auto-immunedisease, more particularly Sjogren's syndrome.
- the subject or the patient is a human being.
- Said human being can be a patient having Sjogren's syndrome, a patient being suspected as having Sjogren's syndrome or at risk of developing Sjogren's syndrome, or a patient suffering from other autoimmune diseases.
- Yet another aspect of the present invention relates to the Identification of the combinations of hnRNP-F- and hnRNP-H1; and the combination of hnRNP-F, hnRNP-E1 and hnRNP-H1; and the combination of hnRNP-A1 and hnRNP-B1; and the combination of hnRNP-B1 and hnRNP-K antibodies as valuable diagnostic marker-combinations in dermatomyositis.
- Yet another aspect of the present invention relates to the identification of the combination of hnRNP-Al- and hnRNP'BI -antibodies as valuable diagnostic marker-combinations in scleroderma.
- Figure 1 Amino Acid (AA) sequence alignments of hnRNP-H1 from mouse, rat and humans. The three sequences (numbers from Swiss-Prot Database) Q8VHV7_RAT (SEQ ID NO:1) , HNRH1 HUMAN
- RNA recognition motifs are indicated by arrows above the AA sequence.
- Figure 2 Homolgy between hnRNP-H1 and hnRNP-F. The complete amino acid sequences were used to calculate the percentage homology. Some regions with particularly high homology between the proteins are shown.
- Figure.3 Prevalence of anti-hnRNP-H1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-H1 -fragment 1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome
- Figure 4 Prevalence of anti-hnRNP-H1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-H1-fragment 2.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line
- Figure 5 Prevalence of anti-hnRNP-H1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-W -fragment
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line
- CVS the disease control group
- Figure 6 Prevalence of anti-hnRNP-H1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-H1-fragment
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line
- Figure 7 Prevalence of anti-hnRNP-A1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-A1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure_ 8 Prevalence of anti-hnRNP-B1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-B1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure 9 Prevalence of anti-hnRNP-C1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-C1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- FIG. 10 Prevalence of anti-hnRNP-E1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-E1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as seriesQ.
- FIG 11 Prevalence of anti-hnRNP-F antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-F.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CFS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CFS (the disease control group), also indicated as series9.
- Figure 12 Prevalence of anti-hnRNP-Gi antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-Gi.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CFS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the ⁇ 7.5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure 13 Prevalence of anti-hnRNP-H1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-H1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure 14 Prevalence of anti-hnRNP-l antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-l.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity In CVS (the disease control group), also indicated as series9.
- FIG. 15 Prevalence of anti-hnRNP-K antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-K SSp: primary Sjogren's syndrome, SLE: systemic lupus erythematosus, MCTD: mixed connective tissue disease, SSc: scleroderma, DM: dermatomyositis, PM: polymyositis, RA: rheumatoid arthritis; CVS: chronic fatigue syndrome.
- the cutoff black horizontal line
- CVS chronic fatigue syndrome
- Figure 16 Prevalence of anti-hnRNP-P2 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-P2.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis.
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure 17 Left panel: 10 hnRNP proteins after 1 -dimensional gelelectrophoresis and staining with Coomassie Brilliant Blue. Middle and right panel: 10 hnRNP proteins subjected to SDS-PAGE and transferred onto a polyvinylidene difluonde membrane. After incubation of the membrane with patient serum, protein-antibody interactions were visualized by use of 3,3'-Diaminobenzidinetetrahydrochloride. Middle panel: serum from a healthy control with negative to light reactivity to different hnRNP's. Right panel: serum from a patient with primary Sjogren's syndrome with strong reactivity to different hnRNP's.
- CTD autoimmune connective tissue diseases
- the figure shows the peak X area value as measured by densitometry for several patient groups.
- the figure shows box plots, from the first to the third quartile, with the addition of a notched section for the confidence interval around the median.
- the whiskers extend to the furthest observations within ⁇ 1.5 interquartile ranges (IQR) of the 1 st or 3rd quartile. Observations outside 1.5 IQRs are marked as (+), and those outside 3.0 IQRs are marked as n.
- IQR interquartile ranges
- CTD autoimmune connective tissue diseases
- the figure shows box plots, from the first to the third quartile, with the addition of a notched section for the confidence interval around the median.
- the whiskers extend to the furthest observations within ⁇ 1.5 interquartile ranges (IQR) of the 1st or 3rd quartile. Observations outside 1.5 IQRs are marked as (+), and those outside 3.0 IQRs are marked as (*).
- IQR interquartile ranges
- SSc connective tissue diseases
- the figure shows box plots, from the first to the third quartile, with the addition of a notched section for the confidence interval around the median.
- the whiskers extend to the furthest observations within ⁇ 1.5 interquartile ranges (IQR) of the 1st or 3rd quartile. Observations outside 1.5 IQRs are marked as (+), and those outside 3.0 IQRs are marked as (*).
- IQR interquartile ranges
- SSc connective tissue diseases
- the figure shows box plots, from the first to the third quartile, with the addition of a notched section for the confidence interval around the median.
- the whiskers extend to the furthest observations within ⁇ 1.5 interquartile ranges (IQR) of the 1st or 3rd quartile. Observations outside 1.5 IQRs are marked as (+), and those outside 3.0 IQRs are marked as (*).
- IQR interquartile ranges
- the invention provides a method of detecting anti-hnRNP-E1 and/or anti- hnRNP-F antibodies in a patient suffering from or susceptible to an autoimmune disease such as Sjogren's syndrome.
- said method additionally detects anti-hnRNP-H1 antibodies in said patient This combined presence of anti-hnRNP-H1, anti-hnRNP-E1 , and anti-hnRNP-F antibodies; and combinations of these antibodies with anti-hnRNP-B1 antibodies (example given anti- hnRNP-H1 and -B1 ; anti-hnRNP-E1 and -B1 ; anti-hnRNP-H1, -B1 and -E1; and anti-hnRNP-H1, -F, -B1 and-E1) are highly specific for SSp and to a lesser extent for MCTD, SLE and DM.
- the method of detecting anti-hnRNP antibodies of the invention includes the step of analyzing a biological sample for the presence of an these antibodies that specifically binds to the specific hnRNP of this invention (such as hnRNP-F).
- any suitable biological sample might be used in the method.
- a biological sample that would normally be expected to contain immunoglobulins might be used.
- the sample would take the form of a bodily fluid, such as blood (and fractions thereof, such as serum or plasma), saliva, tears, mucus, and the like. Because immunoassays are known to generally work well with blood or blood fractions, these are preferred.
- Biological samples can be collected from a subject by any suitable method.
- a blood sample can be collected using conventional phlebotomy procedures; a saliva sample can be collected by spitting or merely by placing a stick in the mouth and is the preferred patient sample. Blood samples can be used for verification of detection of autoantibodies.
- a subject from which a biological sample can be obtained for analysis according to the invention is an animal such as a mammal, e.g. a dog, cat, horse, cow, pig, sheep, goat, primate, rat, or mouse.
- a preferred subject is a human being, particularly a patient suspected of having or at risk for developing an autoimmune disorder such as Sjogren's syndrome (e.g. an individual suffering from dry eye and/or dry mouth), or a patient with a connective tissue disease (e.g. an individual diagnosed with SLE, rheumatoid arthritis, or scleroderma).
- hnRNP-F and hnRNP-H1 antibodies that specifically binds to the specific hnRNPs of this invention
- agents to which these anti-hnRNP antibodies specifically bind are used.
- agents might include a native (i.e. naturally occurring) hnRNP (such as hnRNP-F and hnRNP-H1) or fragments (such as fragment 3 and 4 of hnRNP- H1 , as described in Example2), mutants or variants thereof; or a non-hnRNP test reagent such as an anti- idiotypic antibody.
- hnRNPs such as hnRNP-F and hnRNP-H1
- fragments such as fragment 3 and 4 of hnRNP- H1 , as described in Example2
- non-hnRNP test reagent such as an anti- idiotypic antibody.
- hnRNP-H1 these include those from human, mouse and rat. Generally, those hnRNPs from the same species as the biological sample are preferred for particular variations of the method of the invention. Nonetheless, due to cross-reactivity, non-species matched assays may also be used. For example, rat hnRNP-H1 can be used to detect human anti-hnRNP-Hl antibodies.
- an anti-hnRNP antibody of this invention such as anti- hnRNP-F
- anti-idiotypic anti-hnRNP such as anti-hnRNP-F
- hnRNP such as hnRNP-F
- a test reagent that specifically binds to these proteins a number of different methods might be used.
- the sample, or a purified portion thereof is contacted with the agent under conditions that allow agent-antibody binding.
- the presence of the formed agent-antibody complex is then detected as an indication that the sample contains an anti-hnRNP antibody (such as anti- hnRNP-F).
- hnRNP-expressing cells such as hnRNP-H1 expressing cells for detecting anti-hnRNP-H1 antibodies
- Cell-based detection methods include techniques such as immunohistochemistry, immunofluorescence microscopy, or flow cytometric analysis.
- Non-cell based assays include immunosorbent assays (e.g. ELISA and RIA) and immunoprecipitation assays.
- the hnRNP of this invention e.g.
- hnRNP-H1 is immobilized on a substrate, a human serum sample is placed on the substrate under conditions that would allow binding of said anti-hnRNP antibodies (e.g. anthhnRNP-M antibodies) to the immobilized hnRNP (e.g. hnRNP-H1).
- detectably labeled secondary antibody e.g. an anti- human immunoglobulin antibody if the biological sample was derived from a human subject
- detectable label e.g. an enzyme, fluorophore, or radioisotope
- antibodies contained within a biological sample are immobilized on a substrate, a detectably labeled hnRNP such as hnRNP-H1 is then placed on the substrate under conditions that would allow binding of the immobilized anti-hnRNP antibodies such as anti-hnRNP-H1 antibodies to said hnRNP such as hnRNP-H1.
- hnRNP-H1 antibodies a detectably labeled hnRNP such as hnRNP-H1 antibodies to said hnRNP such as hnRNP-H1.
- detectable label remaining on the substrate after washing indicates that the sample contained these anti-hnRNP antibodies, such as anti- hnRNP-H1 antibodies.
- the method of the invention can be carried out as qualitative or quantitative determination.
- the antibody concentrations which are above the so-called cutoff value are classified as positive.
- the cutoff value can be determined by calibrating the test system with positive and negative control samples. Alternatively, it is also possible to carry out a quantitative determination.
- test format is not in general critical. However, a test format can be preferred in which an immune complex comprising a hnRNP-antigen and the hnRNP autoantibody to be detected is bound to a solid phase. Alternatively, a competitive test format can be envisaged. Solid phases which can be employed are reaction vessels, microtiter plates, beads, biochips etc.
- the antigen can be immobilized on the solid phase by adsorptlve interactions, covalent bonding or mediated by a high-affinity binding pair (streptavidin/biotin, hapten/anti-hapten antibody).
- the immobilized test reagent can be employed in a form which is already bound to a solid phase or else be immobilized only during the test
- the method can be carried out as liquid test (e.g. in a reaction vessel) or else as dry test (e.g. on a test strip).
- the labeled test reagent may itself have a detectable or signal-emitting group (direct labeling) or be capable of binding to a detectable group (indirect labeling).
- the labeling group can be selected as desired from all labeling groups known from the prior art for immunological detection methods, for example from enzymes, metal particles or latex particles, and luminescent or fluorescent groups. It is particularly preferred for the labeling group to be selected from enzymes, e.g. peroxidase, ⁇ -galactosidase or alkaline phosphatase, and for the method to be carried out in the ELISA format.
- Dot blot assay Purified or recombinant hnRNP-F-antigen is spotted on a nitrocellulose or polyvinylidene difluoride (PVDF) membrane.
- the membrane strips are firstly blocked with blocking reagent. After a washing step to remove unbound proteins, they are incubated with diluted serum of the patient, a positive and a negative control serum. They are further washed with washing buffer and treated with alkaline phosphatase labeled protein A conjugate to bind the captured antibodies.
- the purified or recombinant hnRNP-F-antigen is separated on a one dimensional sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) prior to blotting on a membrane.
- SDS-PAGE sodium dodecyl sulfate polyacrylamide gel
- the membrane strip is blocked in blocking buffer (BSA or skim milk powder).
- BSA blocking buffer
- the membrane is subsequently treated with diluted serum of the patient, anti-human IgG conjugated with horseradish peroxidase (HRP) or a fluorescent dye and a substrate to visualize the bound antibodies. Intermittent washing steps will remove the unbound proteins.
- This Western blot assay can be used in combination with other proteins of different molecular weight loaded in the same lane on SDS-PAGE (cfr. line assay). This technique is labor intensive but permits to screen the sera simultaneously for the presence of different auto-antibodies. It's a qualitative method.
- An Enzyme Linked Immunosorbent Assay provides a quantitative in vitro assay for the detection of antibodies.
- Polystyrene microplate strips are coated with purified, biochemically characterized pure or recombinant hnRNP-F-antigen as solid phase. If the sample is positive, specific antibodies in the diluted serum sample attach to the antigens coupled to the solid phase.
- the attached antibodies are detected with peroxidase-labeled anti-human antibodies.
- the bound antibodies are visualized using a chromogen/substrate solution which is capable of promoting a color reaction. The intensity of the color produced is proportional to the concentration of antibodies in the serum sample and is measured using a spectrophotometer with filter settings of a suitable wavelength.
- a Fluoro Enzyme Immuno Assay provides a quantitative in vitro assay for the detection of antibodies.
- a carier e.g. polystyrene microplate strips
- purified, biochemically characterized pure or recombinant antigen e.g. hnRNP-F-antigen
- the attached antibodies are detected with an enzyme-labeled anti-human antibodies.
- the bound antibodies are visualized using a substrate solution which is capable of promoting a color reaction.
- the intensity of the color/fluorescence produced is proportional to the concentration of antibodies in the serum sample and is measured using a spectrophotometer with filter settings of a suitable wavelength.
- the fluorescence of the serum sample is than compared to a standard curve.
- Radio Immuno assays are immuno assays in which radioactive isotopes are used as labels for detection. These assays use gamma and beta counters for detection and are highly sensitive. The greatest disadvantage of radio immuno assays is that the amount of use and the kind of radioisotopes are limited by regulations and radioactive wastes are released in large amounts. Therefore, the RIA is becoming less popular as an immunoassay.
- Bead-based assays Human serum is treated with different sets of color-coded polystyrene beads, each bearing a different antigen (including hnRNP-F). Individual beads bearing interacting antibodies are detected by flow cytometry. The beads are aligned into single files as they enter a stream of sheath fluid and then enter a flow cell. Once the beads are in single file within the flow cell, each bead is individually interrogated for bead color (analyte) and assay signal strength (fluorescence intensity). This is a fast, reproducible and reliable but expensive technique. Only a limited number of antigens can be screened.
- Antigan array Several antigens, including hnRNP-F, are printed on nitrocellulose or superaldehyde coated slides. Printed microarray chips are then washed in wash buffer and probed with diluted patient's serum. Afterwards, fluorescently labeled anti-human IgG conjugate is added and the slides are washed again. The fluorescent signal is further quantified by scanning and image analysis software. These antigen arrays allow to simultaneously screen for the presence of an unlimited amount of autoantibodies.
- Anti-auto-hnRNP antibodies of the invention (such as anti-auto-hnRNP-F anti bodlesyf or therapy
- Anti-autoimmune antibodies or inhibitors) of the present invention include polypeptides comprising the epitope of the antibody or biologically active fragment thereof, or polypeptide that is functional in conferring protection in the individual suffering from autoimmune disease, or functionally conserved fragments or amino acid variants thereof. Identification of the epitope is a matter of routine experimentation. Most typically, one would conduct systematic substitutional mutagenesis of the compound molecule while observing for reductions or elimination of cytoprotective or neutralizing activity. In any case, it will be appreciated that due to the size of many of the antibodies, most substitutions will have little effect on binding activity. The great majority of variants will possess at least some cytoprotective or neutralizing activity, particularly if the substitution is conservative.
- Conservative amino acid substitutions are substitutions from the same class, defined as acidic (Asp, Glu), hydroxy-like (Cys, Ser, The), amides (Asn, Gin), basic (His, Lys, Arg), aliphatic-like (Met, He, Leu, Val, Gly, Ala, Pro), and aromatic (Phe, Tyr, Trp).
- Homologous antibody or polypeptide sequences generally will be greater than about 30 percent homologous on an identical amino acid basis, ignoring for the purposes of determining homology any insertions or deletions from the selected molecule in relation to its native sequence.
- the compounds discussed herein i.e. autoimmune inhibitors for administration to the patient with autoimmune disease and/or for removal, neutralization or inhibition of the autoimmunogen(s) by extracorporeal immunosorption in accordance with the present invention, also include glycosylation variants as well as unglycosylated forms of the agents, fusions of the agents with heterologous polypeptides, and biologically active fragments of the agents, again so long as the variants possess the requisite neutralizing or cytoprotective activity.
- treatments involving administration of an autoimmune inhibitor to a patient may be performed alone or in combination.
- Administered autoimmune inhibitor of the invention binds to, neutralizes and/or inhibits the molecule(s) associated with or causing the autoimmune response in the patient. More specifically, administration of the autoimmune inhibitor to a patient results in suppression of pathological humoral and adaptive immunity in the patient.
- treatment of a patient with the autoimmune inhibitor causes the humoral and adaptive immune response of the patient to be inhibited or neutralized over that which was, or would have been, present in the absence of treatment.
- a patient is in need of treatment with an autoimmune inhibitor, when the patient is suffering from an autoimmune disease or when the patient has produced autoantibodies.
- the autoimmune inhibitor antibody(ies) is also effective when immobilized on a solid support.
- solid supports include, but are not limited to, plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, and acrylic resins, such as polyacrylamide and latex beads. Techniques for coupling antibodies to such solid supports are well known in the artfWeir et a/., "Handbook of experimental Immunology” 4th Ed., Blackwell Scientific Publications, Oxford, England, Chap. 10 (1986); Jacoby et a/., Meth. Enzym. 34 Academic Press, N.Y,(1974)).
- autoantibody gene products may be generated which include proteins that represent functionally equivalent gene products.
- an equivalent hnRNP-F antibody gene product may contain deletions, including internal deletions, additions, including additions yielding fusion proteins, or substitutions of amino acid residues, but that result in a "silent" change, in that the change produces a functionally equivalent auto-hnRNP-F antibody gene product.
- Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
- nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- deletion or non-conservative alterations can be engineered to produce altered anti-hnRNP-F antibody gene products.
- Such alterations can, for example, alter one or more of the biological functions of the autoantibody gene product. Further, such alterations can be selected so as to generate autoantibody gene products that are better suited for expression, scale up, etc. in the host cells chosen. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges. This applies to any autoimmune hnRNP-F molecule and allelic variants thereof, that are identified in an individual.
- the autoantibody gene products, peptide fragments thereof and fusion proteins thereof, of the invention can be produced by recombinant DNA technology using techniques we!i known in the art. Methods that are well known to those skilled in the art can be used to construct expression vectors comprising auto- hnRNP-F antibody gene product coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. See, for example, the techniques described in Sambrook, ef a/., 1989, and Ausubel, ef a/., 1989.
- RNA capable of encoding auto-hnRNP-F antibody gene product sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, ed., IRL Press, Oxford.
- host-expression vector systems may be utilized to express the autoantibodies, such as anti- hnRNP-F gene products.
- Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells that may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the anti- hnRNP-F gene product of the invention in situ.
- the efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner, ef a/., 1987, Methods in Enzymol. 153, 516-544).
- a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g. glycosylation) and processing (e.g. cleavage) of protein products may be important for the function of the protein.
- Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used.
- Such mammalian host cells include but are not limited to CHO, JURKAT, Hep2, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, and W138.
- a variety of methods can be employed for the diagnostic and prognostic evaluation autoimmune disorders such as Sjogren's syndrome and for the identification of subjects having a predisposition to such autoimmune disorders. Such methods may, for example, detect the presence of hnRNP (such as hnRNP- F) gene mutations, or the detection of either over-, under-, or no expression of hnRNP (such as hnRNP- F) protein, or mutants.
- hnRNP such as hnRNP- F
- Mutations at a number of different genetic loci may lead to phenotypes related to autoimmune disorder, structural and synaptic abnormalities.
- the treatment of patients suffering from such disorders will be designed to target the particular genetic loci comprising the mutation mediating the disorder.
- Genetic polymorphisms have been linked to differences in drug effectiveness.
- identification of alterations in hnRNP (such as hnRNP-F) molecules, such as, for example, gene or protein can be utilized to optimize therapeutic drug treatments.
- autoimmune related molecule such as, for example, hnRNP-F, expression levels, mutations, polymorphisms
- a microassay of for example, hnRNP-F nucleic acid sequences immobilized to a substrate or "gene chip" for detection of hnRNP-F molecules see, e.g. Cronin, ef a/., 1996, Human Mutation 7:244-255. Preferred methods are detailed in the examples which follow.
- hnRNP e.g. hnRNP-F
- hnRNP-F hnRNP-F gene expression assays "in situ", i.e. directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary.
- tissue sections fixed and/or frozen
- Antibodies directed against hnRNP such as hnRNP-F gene products may be used in vitro to determine, for example, the level of hnRNP (such as hnRNP-F) antibody gene expression achieved in cells genetically engineered to produce such a gene product.
- hnRNP such as hnRNP-F
- intracellular gene products such an assessment is done, preferably, using cell lysates or extracts. Such analysis will allow for a determination of the number of transformed cells necessary to achieve therapeutic efficacy in vivo, as well as optimization of the gene replacement protocol.
- the tissue or cell type to be analyzed will generally include those that are known, or suspected, to express the hnRNP gene (e.g. the hnRNP-F gene).
- the protein isolation methods employed herein may, for example, be such as those described in Harlow and Lane (1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).
- the isolated cells can be derived from cell culture or from a patient.
- the analysis of cells taken from culture may be a necessary step in the assessment of cells to be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the hnRNP gene (e.g. the hnRNP-F gene).
- Preferred diagnostic methods for the detection of autoimmune molecules may involve, for example, immunoassays wherein the hnRNP-F gene products or conserved variants or peptide fragments are detected by their interaction with an anti-hnRNP-F gene product-specific antibody. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescent!y labeled antibody coupled with light microscopic, flow cytometric, orfluorimetric detection.
- subject or “patienf refers to any human or animal mammals.
- autoimmune disease refers to a disease that result from an aberrant immune response of an organism against its own cells and tissues due to a failure of the organism to recognise its own constituent parts (down to the sub-molecular level) as “self.
- autoimmune disease is intended to further include autoimmune conditions, syndromes and the like.
- autoimmune diseases include, but are not limiting to, Sjogren syndrome, scleroderma, dermatomyositis, polymyositis, rheumatoid arthritis, mixed connective tissue disease, insulin-dependent diabetes mellitus, hemolytic anemias, rheumatic fever, thyroiditis, Crohn's disease, myasthenia gravis, glomerulonephritis, autoimmune hepatitis, multiple sclerosis, and systemic lupus erythematosus.
- an "antigen” as used herein refers to a structure of a macromolecule, typically protein (with or without polysaccharides) or made of proteic composition comprising one or more hapten(s) and/or comprising at least one epitope.
- An “autoantigen” as used herein refers to a human or animal protein present in the body, which elicits an immune response within the same human or animal body, which may in turn lead to a chain of events, including the synthesis of other autoantigens or autoantibodies.
- An “autoantibody” is an antibody (ab) produced by an autoimmune patient to one or more of his own constituents which are perceived to be antigenic. For example, in SLE autoantibodies are produced to DNA, while in many other types of AD autoantibodies are produced to target cells.
- autoimmune diseases including, e.g., rheumatoid arthritis, insulin-dependent diabetes mellitus, hemolytic anemias, rheumatic fever, thyroiditis, Crohn's disease, myasthenia gravis, glomerulonephritis, autoimmune hepatitis, multiple sclerosis, systemic lupus erythematosus and others, are in need of treatment in accordance with the present invention.
- Treatment of patients suffering from these diseases by administration of autoimmune inhibitor and/or removal of compound(s) by extracorporeal immunosorption in accordance with the present invention will alleviate the clinical manifestations of the disease and/or minimize or prevent further deterioration or worsening of the patient's condition.
- Treatment of a patient at an early stage of an autoimmune disease including, e.g., rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, or others, will minimize or eliminate deterioration of the disease state into a more serious condition.
- an autoimmune disease including, e.g., rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, or others, will minimize or eliminate deterioration of the disease state into a more serious condition.
- epitope refers to one or several portions (which may define a conformational epitope) of an antigenic protein which is/are specifically recognised and bound by an antibody or a portion thereof (Fab', Fab2', etc.) or a receptor presented at the cell surface of a B or T cell lymphocyte, and which is able, by said binding, to induce an immune response.
- An epitope can comprise as few as 3 amino acids in a spatial conformation which is unique to the epitope. Generally an epitope consists of at least 6 such amino acids, and more usually at least 8-10 such amino acids.
- Methods for determining the amino acids which make up an epitope include x-ray crystallography, 2-dimensional nuclear magnetic resonance, and epitope mapping e.g.
- the phrase "specifically (or selectively) binds" to an antibody when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologies.
- the specified antibodies bind to a particular protein at least two times the background and do not substantially bind in a significant amount to other proteins present in the sample.
- Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein.
- polyclonal antibodies raised to marker "X" from specific species such as rat, mouse, or human can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with marker "X” and not with other proteins, except for polymorphic variants and alleles of marker "X". This selection may be achieved by subtracting out antibodies that cross-react with marker "X" molecules from other species.
- a variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein.
- solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
- a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.
- Immunoassay Is an assay that uses an antibody to specifically bind an antigen (e.g. a marker).
- the immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantity the antigen.
- Diagnostic means identifying the presence or nature of a pathologic condition. Diagnostic methods differ in their sensitivity and specificity.
- the "sensitivity” of a diagnostic assay is the percentage of diseased individuals who test positive (percent of "true positives”). Diseased individuals not detected by the assay are “false negatives.” Subjects who are not diseased and who test negative in the assay, are termed “true negatives.”
- the "specificity” of a diagnostic assay is 1 (or 100 when indicated as percentage) minus the (percentage) false positive rate, where the "false positive” rate is defined as the proportion of those without the disease who test positive.
- nucleic acid delivery vector may be provided as naked nucleic acids or in a delivery vehicle associated with one or more molecules for facilitating entry of a nucleic acid into a cell.
- Suitable delivery vehicles include, but are not limited to: liposomal formulations, polypeptides; polysaccharides; lipopolysaccharides, viral formulations (e.g. including viruses, viral particles, artificial viral envelopes and the like), cell delivery vehicles, and the like.
- liposomal formulations polypeptides
- polysaccharides polysaccharides
- lipopolysaccharides lipopolysaccharides
- viral formulations e.g. including viruses, viral particles, artificial viral envelopes and the like
- cell delivery vehicles e.g. including viruses, viral particles, artificial viral envelopes and the like
- hnRNPs as new target of auto-antibodies in patients with autoimmune diseaes such as Sjogren's syndrome.
- Antibodies to hnRNP-A1, -B1. .-C1 , -E1, -F , -H1, -I, -K, and -92 were all significantly detected in patients with primary Sjogren's syndrome (see Table 1 and 2 in Example 2).
- Certain combinations of these hnRNP-markers are extremely relevant for the diagnosis of autoimmune diseaes such as Sjogren's syndrome. These combinations comprise the ones depicted in grey background color in Table 4.
- hnRNP-markers to detect Sjogren's syndrome are 'hnRNP-F and -H1', 'hnRNP-E1 , and -F', 'hnRNP-EI, -F, and -B1'.
- hnRNP-EI, -F, and -HT and 'hnRNP-A1 , -B1, -E1 , ⁇ F, and -H1'.
- a method comprising the analysis of this combination of markers (hnRNP-E1 , -F, and -H1) can be used to diagnose patients for Sjogren's syndrome, mixed connective tissue disease (MCTD), dermatomyositis (DM) and SLE.
- MCTD mixed connective tissue disease
- DM dermatomyositis
- a method comprising the analysis of this combination of markers (hnRNP-B1 and -A1) can be used to diagnose patients for SSc.
- single antibodies to hnRNP-AI, -B1, -E1, -F, and -H1 are detected in more than 37% of the
- 'hnRNP-E1 ( and -F; "hnRNP-EI , -F, and -B1'; 'hnRNP-E1, -F, -H1 , and ⁇ B1'; 'hnRNP-A1 , - B1 , -F, and -HT; 'hnRNP-E1, -F, and ⁇ H1"; and 'hnRNP-A1, -B1 , -E1 , -F, and -H1', are useful in methods for diagnosing Sjogren's syndrome.
- fragments of hnRNP-H1 were analysed as markers for several autoimmuun diseases.
- fragments 1 , 2, 3 and 4 of hnRNP-H1 are useful as a marker for Sjogren's syndrome.
- Fragments 2, 3 and 4 show the highest positive values for Sjogren's syndrome in Table 1 indicating that most antibodies to hnRNP-H1 in Sjogren's syndrome patients recognize these fragments.
- fragments 2 and 4 of hnRNP-H1 are extremely homologue to certain regions (the RRM1 en 2 regions respectively) in hnRNP-F (as shown in Fig 2), indicating that these hnRNP-H1 and -F markers and more particularly the aforementioned regions/fragments or amino acid sequences that are higly homologues to these regions/fragments (preferably more than 80, 85, ⁇ 0, or 95 % homologues to the aforementioned regions/fragments in hnRNP-H1 or -F) are good candidate markers for Sjogren's syndrome.
- fragment 4 or amino acid sequences that are higly homologues to this fragment (preferably more than 80, 85, 90, or 95 % homolgy) are good candidate markers for autoimmune diseases, in particular Sjogren's syndrome.
- hnRNP-B1 The high reactivity to hnRNP-B1 , hnRNP-E1, and hnRNP-F in Sjogren's syndrome was confirmed by ELISA.
- ELISA did not reveal significantly higher reactivity for hnRNP-H1 in Sjogren's syndrome than in controls. This might be related to differences in conformation of the protein between ELISA and Western blotting.
- Antibodies to hnRNP B1 were found in Sjogren's syndrome and in several other connective tissue diseases including mixed connective tissue disease and systemic lupus erythematosus.
- ELISA analysis further confirmed the notion that the simultaneous presence of antibodies to several hnRNPs was strongly associated with connective tissue disease in general and Sjogren's syndrome in particular. For example, reactivity to at least 2 of the 4 tested antigens was found in 1.1% of controls, in 16% of patients with systemic lupus erythematosus, and in 18% of patients with Sjogren's syndrome. Reactivity to at least 3 of the 4 antigens was found in none of the controls and in 15% of patients with Sjogren's syndrome.
- ELISA analyses were done on diagnostic samples (i.e. samples that were obtained at the time of diagnosis).
- diagnostic samples i.e. samples that were obtained at the time of diagnosis.
- 19 tested positive for at least 1 of the four antigens tested hnRNP-B1, -E1, -F and -H1).
- Two of these patients were negative for anti-SSA or anti-SSB antibodies.
- diagnostic samples from patients with systemic lupus erythematosus and with systemic sclerosis that were negative for the classical antibodies to extractable nuclear antigens and to dsDNA but positive for antibodies to hnRNPs.
- hnRNP-A1 and -B1 showed 60.5% identity. Both proteins have two moderate homologous RRM's and a glycine rich region. HnRNP-Hl and -F have an identity of 78%. Even though the proteins are closely sequence-related, they exhibit differences, especially in their COOH terminus, where hnRNP-F is shorter and contains a deletion when compared with hnRNP-H1. These differences occur outside the RRM regions.
- hnRNP-F and -H1 are highly related immunologically.
- several hnRNP's are target antigens in Sjogren's syndrome.
- the combined presence of antibodies to several hnRNP's was strongly associated with connective tissue disease in general and Sjogren's syndrome in particular.
- hnRNP-E1 and hnRNP-F new targets of autoantibodies in patients with an autoimmune diseases, in particular Sjogren's syndrome. Therefore, we identified these antibodies and combinations of these antibodies as valuable diagnostic markers in autoimmune diseases, in particular Sjogren's syndrome.
- the second group of samples consisted of diagnostic samples (i.e. samples obtained at the time of diagnosis).
- CFS chronic fatigue syndrome
- CVS chronic fatigue syndrome
- hnRNP A1, HT, F and I obtained from Douglas Black, Howard Hughes Medical Institute, LA
- hnRNP P2 obtained from Takumi, Osaka Bioscience, Institute Japan
- hnRNP E1 en K obtained from Kent Duncan, University of Berlin
- hnRNP G obtained from Chiou, National Chung Hsing University, Taiwan
- hnRNP C1 obtained from Chang, National Taiwan University, Taiwan was used.
- cDNA of hnRNP B1 was constructed by isolation of RNA out of HeLa cells by means of the RNeasy mini kit (Qiagen). RNA was converted to cDNA using the RevertAid H Minus First Strand synthesis kit (Fermentas).
- PCR product was first cloned in the plasmid pDONR-221 using a BP clonase reaction and subsequently in the expression plasmid pDEST-17 by a LR cionase reaction.
- the gene was extended with a hexahistidine (6x His) coding sequence at its 5' end upon cloning in the pDEST-17 vector. Thereafter, expression was induced in E.
- Protein-antibody interactions were visualized by use of 0.7 mmol/L 3,3'- diaminobenzidinetetrahydrochloride. Blotting signals were scanned with a CanoLiDE25 (Canon) scanner and quantified by ImageJ software (Image Processing and Analysis in Java). We included a positive and negative control serum sample in each run. The CV of the positive control (for all proteins) was ⁇ 25% over 103 runs.
- immobilizer amino plates (Nunc) were coated 2 hours at room temperature with 100 ⁇ per well with iMg/ml hnRNP B1 p E1, F or HI. After washing the plates four times with 1x PBS-Tween 20 (0.05%), 50 ⁇ of serum sample was added (dilution 1 :50 in PBS). The plates were incubated at room temperature for 30 min. Thereafter, 100 ⁇ of horseradish peroxidase-conjugated goat anti-human IgG (diluted 1 :5000 in PBS) was added to each well and the plates were incubated at room temperature for 30 min. Between each step, the plates were washed four times with 1x PBS-Tween 20 (0.05%).
- the color reaction was developed using 3,3',5,5'-tetramethylbenzidine as substrate (100 ⁇ per well). The wells were incubated in the dark at room temperature for 15 min. This enzymatic coloration was stopped by addition of 100 ⁇ 0.5M H2S04 and the optical density was measured at 450 nm. A positive sample was used as standard. To this standard (six bi-fold serial dilutions starting from 1/50 to 1/1600), 100 arbitrary units were assigned. In each run, a positive and a negative control were included. The optical density of the samples was measured. Arbitrary units were calculated based on a standard curve. The coefficient of variation of the positive control (for all antigens) was ⁇ 13% over 12 runs.
- hnRNP-H1 was described as a newly recognized target of autoantibodies. These antibodies were mainly found in patients with Sjogren's syndrome, but were also present in patients with other autoimmune-mediated diseases (WO2009055880). Characterization of reactive epitopes allows us to study the mechanism of epitope spreading and to simplify the design of detection methods for the fast detection of autoantibodies. In addition we want to examine whether positivity against a specific epitope can be linked with a characteristic pathology or clinical phenotype. Previous epitope mapping studies proved that with some hnRNPs, like hnRNP A, B en D, the prominent antibody binding sites are localized at the RNA Recognition Motifs (RRMs).
- RRMs RNA Recognition Motifs
- HnRNP-H1 was split up in five separate fragments (1-5) and these were expressed as recombinant oligopeptides.
- the choice of the restriction sites was made based on the location of the RRMs and the secondary structure of the hnRNP-H1 protein.
- the five different fragments that are generated (and His-tagged) in this study are: Fragment 1 (AminoAcid (AA) 1-110):
- Fragments 1 to 4 are used to study the prevalence of antibodies recognizing these fragments in patients with autoimmune connective tissue disorders and the results are shown in Fig. 3 to 6. Fragment 3 and 4 appear to be the antigens with the largest antibody binding capacity. No antibodies to fragment 5 could be detected.
- the objective of this study was to evaluate the value of antibodies against different hnRNP proteins in patients with a connective tissue disease and in diseased controls (DC).
- a total of 404 sera from patients with different systemic rheumatic diseases was tested for reactivity to 10 recombinant human hnRNP proteins (with numbers from UniProtKB/Swiss-Prot Database: hnRNP-A1 (P09651), -B1 (P22626), - C1(P07910), -E1(Q1S365), -F (P52597), -Gi (P38159), -H1 (P31943), -I (Q9BUQ0), -K (P61978) and -P2 (P35637)).
- Recombinant proteins were produced according to the Gateway Cloning System. Constructs were transformed in E. coli BL21AI competent cells, and expressed as His-tagged fusion proteins. The identity of the proteins was confirmed by MALDI-TOF/TOF. Reactivity of serumantibodies to hnRNPs was tested by Gel electrophoresis and Western blotting. Statistical significance was evaluated by Mann- Whitney and Fisher exact testing. The results that show the prevalence of antibodies recognizing these 10 different hnRNPs in patients with autoimmune connective tissue disorders are depicted in Fig. 7 to 16. The results of this study are summarized in the next tables.
- Table 1 Summary of prevalences of antibodies to the hnRNP proteins and fragments 1, 2, 3 and 4 of hnRNP-H1 in different systemic rheumatic diseases. Values are percentages with a cutoff set at 97,5 % specificity in CVS, the disease control (DC).
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- A, B, C, E, F, Gi, H, I, K, P, and 1 , 2, 3, and 4 stand for hnRNP-A1, -B1, -C1 , -E1 , -F, -Gi. -H1 , -I, -K, -P2, and fragment 1 , 2, 3 and 4 of hnRNP-H1 respectively.
- Table 2 Summary of the fisher exact statistical analyses of ail specific Abs tested. Statistically significant differences in prevalence were assessed by Fisher exact test for the comparison between the diseased and the control (CVS) group. The significant values (pO.05) are indicated in grey background.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- A, B, C, E, F, Gi, H, I, K, P, and 1, 2, 3, and 4 stand for hnRNP-A1 , -B1, -C1, - E1, -F, -Gi, -H1, -I, -K, -P2, and fragment 1, 2, 3 and 4 of hnRNP-H1 respectively. P values are not corrected for multiple comparisons.
- Table 3 This table shows the results for Mann-Whitney statistical analysis between each diseased group and the control group (CVS). The significant values (p ⁇ 0.05) are indicated in grey background.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- A, B, C, E, F, Gi, H, I, K, P, and 1 , 2, 3, and 4 stand for hnRNP-A1, -B1, -C1, - E1 , -F, -Gi, -H1, -I, -K, -P2, and fragment 1, 2, 3 and 4 of hnRNP-H1 respectively. P values are not corrected for multiple comparisons.
- Table 4 Summary of the simultaneous presence of Abs to different hnRNPs used in this study. The significant values (p ⁇ 0.05, Fisher-exact, see Table 5) are indicated in grey background.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CFS chronic fatigue syndrome.
- A, B, E, F, H, I, and K stand for hnRNP-A1, -B1 , -E1, -F, -HI, -I, and -K respectively.
- A, B, E, F, H, I, and K stand for hnRNP-AI , -B1, -Ei, -F, -H1, -I, and -K respectively.
- the simultaneous presence of antibodies to hnRNP A1 and B1 was associated with DM, Ssc and SSp, while the simultaneous presence of antibodies to hnRNP H1 and F was associated with DM and SSp.
- the simultaneous presence of antibodies to hnRNP B1 and K was associated with DM and SSp, and the simultaneous presence of antibodies to hnRNP E1 , F and H1 was associated with DM, MCTD and SSp.
- Patients with DM have also combined presence to several hnRNPs. More than 20% has combined Abs to A1 and B1, and 17% has Abs to F and H1, and to B1 and K.
- Figures 18 and 9 show the reactivity to a selection of 8 hnRNP's in controls, In patients with systemic sclerosis, in patients with Sjogren's syndrome, and in patients with a connective tissue disease other than systemic sclerosis or Sjogren's syndrome. For all antigens the highest reactivity was found in Sjogren's syndrome. For all antigens, except Gi, the reactivity was statistically significantly higher in Sjogren's syndrome than controls , systemic sclerosis, and connective tissue diseases other than Sjogren's syndrome (p ⁇ 0.05 Kruskall Wallis with Bonferroni correction). The reactivity in connective tissue diseases other than Sjogren's syndrome and systemic sclerosis was higher than the reactivity in controls and in systemic sclerosis for all antigens except hnRNP Gi and hnRNP K.
- Antibodies to hnRNP A1, hnRNP B1 , and hnRNP P2 were significantly more prevalent in mixed connective tissue disease than in controls, and antibodies to hnRNP At, hnRNP B1 , and hnRNP F were significantly more prevalent in dermatomyositis than in controls. Reactivity to at least 1 of the 10 antigens was found in 19% of controls and in 45% of dermatomyositis, 49% of rheumatoid arthritis, 38% of systemic lupus erythematosus, 53% of mixed connective tissue disease, and 73% of Sjogren's syndrome.
- Reactivity to at least 3 antigens was found in 2% of controls, 14% of systemic sclerosis, 27% of dermatomyositis, 14% of systemic lupus erythematosus, 26% of mixed connective tissue disease, and 48% of Sjogren's syndrome. Reactivity to at least 5 antigens was found in none of the controls, 7% of systemic sclerosis, 14% of dermatomyositis, 7% of systemic lupus erythematosus, 18% of mixed connective tissue disease, and 32% of Sjogren's syndrome (Table 7).
- Reactivity to at least 1 of the 4 tested antigens was found in 11% of the controls, 35% of rheumatoid arthritis, 47% of systemic lupus erythematosus, 64% of mixed connective tissue disease, and 56% of Sjogren's syndrome.
- Reactivity to at least 2 of the 4 tested antigens was found in 1.1% of controls, in 16% of patients with systemic lupus erythematosus, and in 18% of patients with Sjogren's syndrome.
- Reactivity to at least 3 of the 4 antigens was found in none of the controls and in 15% of patients with Sjogren's syndrome. 061
- Table 9 Antibodies to four hnRNP proteins (B1, E1, F, H1) were determined by ELISA.
- the table summarizes the combined reactivity to these antigens in various connective tissue diseases [systemic sclerosis (SSc), polymyositis (PM), dermatomyositis (DM), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjogren's syndrome (SS)], in controls, and in blood donors.
- SSc systemic sclerosis
- PM polymyositis
- DM dermatomyositis
- RA rheumatoid arthritis
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SS Sjogren's syndrome
- the present invention relates to new methods of diagnosing several autoimmune diseases. More particularly the present invention relates to methods and compositions for detecting anti-heterogeneous nuclear ribonucleoprotein autoantibodies for diagnosing these autoimmune diseases. More in particular, the present invention relates to methods and compositions for detecting anti- heterogeneous nuclear ribonucleoproteins-EI , -F, -H1, -A1 , and -B1, including any combinations of these, for diagnosing autoimmune diseases, more in particular for diagnosing Sjogren's syndrome, mixed connective tissue disease (MCTD) and dermatomyositis (DM).
- MCTD mixed connective tissue disease
- DM dermatomyositis
- Autoantibodies to intracellular antigens are a common feature of systemic autoimmune disorders such as systemic lupus erythematosus (SLE), systemic sclerosis (Ssc), polymyositis (PM), mixed connective tissue disease (MCTD), dermatomyositis (DM), primary Sjogren's syndrome (SSp) or rheumatic arthritis (RA).
- SLE systemic lupus erythematosus
- Ssc systemic sclerosis
- PM polymyositis
- MCTD mixed connective tissue disease
- DM dermatomyositis
- SSp primary Sjogren's syndrome
- RA rheumatic arthritis
- These autoantibodies are typically directed to sets of proteins associated with discrete supramolecular entities built up of either DNA or RNA and proteins, such as the nucleosome, the centromere, the spliceosome, the ribosome or other RNPs.
- HnRNPs comprise a group of approximately 30 different proteins. They mainly play a role in processing of precursor mRNA, but are also involved in telomeric DNA synthesis and cellular apoptotic processes. HnRNPs are composed of at least 1 RNA recognition motif. HnRNP proteins appear to be an important target of autoimmune responses. Several different hnRNP proteins have been described as autoantigens in autoimmune connective tissue diseases.
- Anti-hnRNP A2 antibodies target the 36 kDa hnRNP A2 as well as its alternatively spliced variants hnRNP B1 (37 kDa) en B2 (38 kDa).
- RA33 complex shows reactivity with autoantibodies in 35% of RA patients, 38% of MCTD patients, 23% of SLE patients and not in patients with other rheumatic diseases.
- RA33 complex shows reactivity with autoantibodies in 35% of RA patients, 38% of MCTD patients, 23% of SLE patients and not in patients with other rheumatic diseases.
- Soulard ef al. identified antibodies reacting with hnRNP G.
- the same research group characterized a new antibody specificity in a panel of sera from dogs developing SLE.
- the target antigen was found to be a C protein of the hnRNP complex.
- hnRNP K rheumatic diseases hnRNP K as autoantigen in 44% of SLE patients, in 18% of patients with MCTD and in 14% of RA patients.
- Caporali et al. found reactivity against hnRNP I in patients with systemic sclerosis, but not in patients with SLE, RA of MCTD.
- HnRNP D was identified by Skriner et al. as a new autoantigen in patients with SLE and related disorders.
- Antibodies to hnRNP R were found in
- hnRNP H1 was described as a newly recognized target of autoantibodies. These antibodies were mainly found in patients with Sjogren's syndrome, but were also present in patients with other autoimmune-mediated diseases (WO2009055880).
- Sjogren's syndrome is an autoimmune exocrinopathy, characterized by dryness of the mouth and eyes resulting from a chronic loss of secretory function of the salivary and lacrimal glands.
- Extraglandular systemic manifestations are common and include abnormalities of skin, arthralgia, myalgia, thyroiditis, and pulmonary, renal, gastrointestinal, hematological, cardiac, and neurological abnormalities.
- the etiology of the disease remains unclear. The prevalence of the disease is estimated to be 0.5% and there is a female preponderance.
- Pathological findings involve focal lymphocytic infiltration of affected tissues.
- Anti-SSA antibodies are found in 45-90% of the patients with Sjogren's syndrome.
- Anti-SSB antibodies are found slightly less commonly.
- Anti-SSA antibodies are not specific for Sjogren syndrome as they are found in other systemic diseases such as systemic lupus erythematosus, subacute cutaneous lupus erythematosus and neonatal lupus.
- Sjogren's syndrome can occur in two forms: primary Sjogren's syndrome (not associated with other autoimmune diseases) and secondary Sjogren's syndrome (associated with other autoimmune diseases). Because of the non-specific symptoms (dry eyes and mouth), establishment of the diagnosis of Sjogren's syndrome may be difficult. There is an unmet need for additional accurate and valid diagnostic markers. A number of new autoantigens have recently been suggested: oc-fodrin, muscarinic M3 acetylcholine receptor, SS-56, which is structurally related to the 52 kDa SSA antigen, and hnRNP H1.
- the present invention shows several hnRNPs as a new targets of autoantibodies in patients with autoimmune diseases.
- These hnRNPs are selected from the group consisting of hnRNP-A1 , hnRNP-B1 ,
- the hnRNPs as targets of antibodies in Sjogren's syndrome are one or more hnRNPs selected from the group consisting of hnRNP-A1 , hnRNP-B1 , hnRNP-CI , hnRNP-E1 , hnRNP-F, hnRNP-l, hnRNP-K, and hnRNP- P2.
- the one or more hnRNPs from said group can be combined with hnRNP-H1 as combined markers for Sjogren's syndrome.
- the present invention identifies hnRNP-F; hnRNP-E1 ; and the combination of hnRNP-F and hnRNP-E1 as very valuable diagnostic markers and marker-combinations in Sjogren's syndrome.
- the present invention also identifies the following combination of antibodies as very valuable diagnostic combination markers in Sjogren's syndrome: hnRNP-F and hhRNP-H1 ; hnRNP-E1 and hnRNP-H1; and the combination of hnRNP-F, -E1 , and -H1 ; and the combination of hnRNP-B1 , -F, and -E1 ; and the combination of hnRNP-B1 , -F, -E1 , and -H1.
- the present invention also identifies additional antibody markers (for example hnRNP-A1) which in combination with any of the above mentioned 4 diagnostic antibody markers and their combinations (hnRNP-E1 , -F, -H1 and -B1) that are useful diagnostic antibody marker combinations in Sjogren's syndrome (examples are the combination of hnRNP-A1 , -B1 , and -F; the combination of hnRNP-A1 , -B1 , -F, and -E1 ; the combination of hnRNP-A1 , -B1 , -F, and -H1; and the combination of hnRNP-A1 , -B1 , -F, and -HI).
- additional antibody markers for example hnRNP-A1 which in combination with any of the above mentioned 4 diagnostic antibody markers and their combinations (hnRNP-E1 , -F, -H1 and -B1) that are useful diagnostic antibody marker combinations in
- markers and markercombinations that are also valuable diagnostic markers and marker-combinations for other autoimmune diseases, more in particular the hnRNP-F; hnRNP-E1 ; and the combination of hnRNP-F and hnRNP-E1 markers (including the combinations of these markers with the markers hnRNP-H1 and/or hnRNP-B1 , example given hnRNP-E1 and hnRNP-H1; hnRNP-F and hnRNP-H1 ; hnRNP-F, -E1 , and -HI ; hnRNP-E1 , -F, and -B1 ; and hnRNP-E1 , -F, -H1 and -B1,) are useful markers for mixed connective tissue disease, systemic lupus erythematosus, and dermatomyositis.
- the present invention provides for a method for diagnosing Sjogren's syndrome. More particularly the present invention provides methods and compositions for detecting the above mentioned anti-hnRNP autoantibodies for diagnosing Sjogren's syndrome.
- the method of this invention is applicable to a large group of patients, including patients having Sjogren's syndrome, patients being suspected as having Sjogren's syndrome or at risk of developing Sjogren's syndrome, or patients suffering from other autoimmune diseases.
- One aspect of the present invention relates to a method of diagnosing an autoimmune disease, more particularly Sjogren's syndrome, characterized in that the presence of autoantibodies against the above mentioned hnRNPs and the above mentioned combinations is determined in an isolated biological sample derived from a subject.
- the present invention relates to methods of diagnosing autoimmune diseases, more in particular Sjogren's syndrome, by measuring the presence of autoantibodies against the above mentioned hnRNPs and the above mentioned combinations in an isolated biological sample derived from a subject, and wherein the presence of the above mentioned hnRNPs or the above mentioned combinations is indicative for the diagnosis of said autoimmunedisease for said subject, or wherein the presence of the above mentioned hnRNPs or the above mentioned combinations is indicative for the predisposition of said subject to develop said autoimmunedisease.
- the present invention further relates to a method for detecting the above mentioned hnRNP antibodies and the above mentioned combinations in an isolated biological sample, the method comprising the steps of (a) obtaining an isolated biological sample from a patient; and (b) analyzing said isolated biological sample for the presence of antibodies against said hnRNPs.
- said method is characterized in that the corresponding hnRNP proteins, peptides, variants or fragments thereof are used for determining the presence of the above mentioned hnRNP antibodies and the above mentioned combinations.
- said method is characterized in that a hnRNP antigen, more specific an immobilized hnRNP antigen is used for determining the presence of the corresponding hnRNP antibodies.
- said analysis or determination of the presence of autoantibodies against the hnRNPs of this invention is performed in an immunoassay.
- said immunoassay is selected from the group consisting of ELISA, FEIA, western blot, dot blot, bead-based assay, antigen array and Radio Immuno Assay.
- the methods of the invention are used for predicting responsiveness to a medicament.
- Another aspect of the present invention relates to the use of hnRNP proteins of this invention (including the above mentioned hnRNPs and the above mentioned combinations), peptides, variants or fragments thereof to detect the presence of autoantibodies against said hnRNPs in an isolated biological sample derived from a subject.
- the present invention further relates to the use of said hnRNP proteins, peptides, variants or fragments thereof to detect the presence of autoantibodies against said hnRNPs in an isolated biological sample derived from a patient for diagnosing an autoimmune disease, more particularly Sjogren's syndrome.
- the isolated biological sample is a fluid selected from the group consisting of blood, serum, plasma, saliva, tears, mucus and ascites fluid; and preferentially said biological sample is serum.
- said isolated biological sample is derived from blood, plasma, serum, saliva, tears, lymph, urine, cerebrospinal fluid, any biopsy material or tissue sample, including bone marrow, lymph nodes, nervous tissue, skin, hair, fetal material including amniocentesis material, uterine tissue, faeces or semen.
- said isolated biological sample is an antibody-containing isolated biological sample.
- test kit for detecting the presence of antibodies against the hnRNPs of this invention (including the above mentioned hnRNPs and the above mentioned combinations) in an isolated biological sample.
- the test kit additionally comprises a solid phase onto which said antigen is or can be bound.
- the test kit additionally comprises a labeling group which is bound to said antigen or can be bound thereto.
- the test kit additionally comprises at least one other antibody class-specific test reagent.
- the test kit may additionally comprise other conventional reagents such as buffers, substrates and wetting solutions.
- the present invention further relates to the use of said test kit for carrying out any of the methods of the invention.
- Another aspect of the present invention relates to a method of treating an autoimmune disease, more particularly Sjogren's syndrome, comprising administering to a patient an inhibitor that specifically binds to the hnRNP autoantibodies of said patient, in an amount effective to treat the autoimmune disease, more particularly Sjogren's syndrome.
- said inhibitor is selected from the group consisting of hnRNP-E1 and hnRNP-F proteins, peptides, variants, fragments, epitopes, or combinations thereof and an antibody, in particular an antibody that recognizes and inhibits said autoantibodies.
- the present invention further relates to the use of a compound which specifically binds to at least one group of hnRNP autoantibodies or the combination of certain autoantibodies (as described herein above) for the production of a medicine.
- said medicine is used for the treatment of an auto-immunedisease, more particularly Sjogren's syndrome.
- the subject or the patient is a human being.
- Said human being can be a patient having Sjogren's syndrome, a patient being suspected as having Sjogren's syndrome or at risk of developing Sjogren's syndrome, or a patient suffering from other autoimmune diseases.
- Yet another aspect of the present invention relates to the identification of the combinations of hnRNP-F- and hnRNP-H1 ; and the combination of hnRNP-F, hnRNP-E1 and hnRNP-H1 ; and the combination of hnRNP-A1 and hnRNP-B1 ; and the combination of hnRNP-B1 and hnRNP-K antibodies as valuable diagnostic marker-combinations in dermatomyositis.
- Yet another aspect of the present invention relates to the identification of the combination of hnRNP-A1- and hnRNP-B1 -antibodies as valuable diagnostic marker-combinations in scleroderma.
- Figure 1 Amino Acid (AA) sequence alignments of hnRNP-H1 from mouse, rat and humans. The three sequences (numbers from Swiss-Prot Database) Q8VHV7_RAT (SEQ ID NO:1) , HNRH1 HUMAN
- RNA recognition motifs are indicated by arrows above the AA sequence.
- Figure 2 Homolgy between hnRNP-H1 and hnRNP-F. The complete amino acid sequences were used to calculate the percentage homology. Some regions with particularly high homology between the proteins are shown.
- Figure 3 Prevalence of anti-hnRNP-H1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-H1-fragment 1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome
- Figure 4 Prevalence of anti-hnRNP-H1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-H1-fragment 2.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line
- Figure 5 Prevalence of anti-hnRNP-H1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-H1-fragment
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line
- CVS the disease control group
- Figure 6 Prevalence of anti-hnRNP-H1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-H1-fragment
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line
- CVS the disease control group
- Figure 7 Prevalence of anti-hnRNP-A1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-A1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure 8 Prevalence of anti-hnRNP-B1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-B1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure 9 Prevalence of anti-hnRNP-C1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-C1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- FIG. 10 Prevalence of anti-hnRNP-E1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-E1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- FIG 11 Prevalence of anti-hnRNP-F antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP ⁇ F.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CFS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CFS (the disease control group), also indicated as series9.
- Figure 12 Prevalence of anti-hnRNP-Gi antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-Gi.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CFS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure 13 Prevalence of anti-hnRNP-H1 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-H1.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure 14 Prevalence of anti-hnRNP-l antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-l.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- FIG. 15 Prevalence of anti-hnRNP-K antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-K.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure 16 Prevalence of anti-hnRNP-P2 antibodies in patients with autoimmune connective tissue disorders by performing a Western blotting analysis using recombinant His-tagged hnRNP-P2.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- the cutoff black horizontal line was set at the 97,5 % specificity in CVS (the disease control group), also indicated as series9.
- Figure 17 Left panel: 10 hnRNP proteins after 1-dimensional gelelectrophoresis and staining with Coomassie Brilliant Blue. Middle and right panel: 10 hnRNP proteins subjected to SDS-PAGE and transferred onto a polyvinylidene difluoride membrane. After incubation of the membrane with patient serum, protein-antibody interactions were visualized by use of 3,3'-Diaminobenzidinetetrahydrochloride. Middle panel: serum from a healthy control with negative to light reactivity to different hnRNP's. Right panel: serum from a patient with primary Sjogren's syndrome with strong reactivity to different hnRNP's.
- the figure shows box plots, from the first to the third quartile, with the addition of a notched section for the confidence interval around the median.
- the whiskers extend to the furthest observations within +1.5 interquartile ranges (IQR) of the 1st or 3rd quartile. Observations outside 1.5 IQRs are marked as (+), and those outside 3.0 IQRs are marked as C).
- IQR interquartile ranges
- CTD autoimmune connective tissue diseases
- the figure shows box plots, from the first to the third quartile, with the addition of a notched section for the confidence interval around the median.
- the whiskers extend to the furthest observations within ⁇ 1.5 interquartile ranges (IQR) of the 1st or 3rd quartile. Observations outside 1.5 IQRs are marked as (+), and those outside 3.0 IQRs are marked as (*).
- IQR interquartile ranges
- SSc connective tissue diseases
- the figure shows box plots, from the first to the third quartile, with the addition of a notched section for the confidence interval around the median.
- the whiskers extend to the furthest observations within ⁇ 1.5 interquartile ranges (IQR) of the 1st or 3rd quartile. Observations outside 1.5 IQRs are marked as (+), and those outside 3.0 IQRs are marked as (*).
- IQR interquartile ranges
- SSc connective tissue diseases
- the figure shows box plots, from the first to the third quartile, with the addition of a notched section for the confidence interval around the median.
- the whiskers extend to the furthest observations within ⁇ 1.5 interquartile ranges (IQR) of the 1st or 3rd quartile. Observations outside 1.5 IQRs are marked as (+), and those outside 3.0 IQRs are marked as (*).
- IQR interquartile ranges
- the invention provides a method of detecting anti-hnRNP-E1 and/or anti- hnRNP-F antibodies in a patient suffering from or susceptible to an autoimmune disease such as Sjogren's syndrome. In another preferred embodiment said method additionally detects anti-hnRNP-H1 antibodies in said patient.
- anti-hnRNP-H1 , anti-hnRNP-E1 , and anti-hnRNP-F antibodies are highly specific for SSp and to a lesser extent for MCTD, SLE and DM.
- the method of detecting anti-hnRNP antibodies of the invention includes the step of analyzing a biological sample for the presence of an these antibodies that specifically binds to the specific hnRNP of this invention (such as hnRNP-F).
- any suitable biological sample might be used in the method.
- a biological sample that would normally be expected to contain immunoglobulins might be used.
- the sample would take the form of a bodily fluid, such as blood (and fractions thereof, such as serum or plasma), saliva, tears, mucus, and the like. Because immunoassays are known to generally work well with blood or blood fractions, these are preferred.
- Biological samples can be collected from a subject by any suitable method.
- a blood sample can be collected using conventional phlebotomy procedures; a saliva sample can be collected by spitting or merely by placing a stick in the mouth and is the preferred patient sample. Blood samples can be used for verification of detection of autoantibodies.
- a subject from which a biological sample can be obtained for analysis according to the invention is an animal such as a mammal, e.g. a dog, cat, horse, cow, pig, sheep, goat, primate, rat, or mouse.
- a preferred subject is a human being, particularly a patient suspected of having or at risk for developing an autoimmune disorder such as Sjogren's syndrome (e.g. an individual suffering from dry eye and/or dry mouth), or a patient with a connective tissue disease (e.g. an individual diagnosed with SLE, rheumatoid arthritis, or scleroderma).
- hnRNP-F and hnRNP-H1 antibodies that specifically binds to the specific hnRNPs of this invention
- agents to which these anti-hnRNP antibodies specifically bind are used.
- agents might include a native (i.e. naturally occurring) hnRNP (such as hnRNP-F and hnRNP-H1) or fragments (such as fragment 3 and 4 of hnRNP- H1 , as described in Example2), mutants or variants thereof; or a non-hnRNP test reagent such as an anti- idiotypic antibody.
- hnRNPs such as hnRNP-F and hnRNP-H1
- fragments such as fragment 3 and 4 of hnRNP- H1 , as described in Example2
- non-hnRNP test reagent such as an anti- idiotypic antibody.
- hnRNP-H1 these include those from human, mouse and rat. Generally, those hnRNPs from the same species as the biological sample are preferred for particular variations of the method of the invention. Nonetheless, due to cross-reactivity, non-species matched assays may also be used. For example, rat hnRNP-H1 can be used to detect human anti-hnRNP-H1 antibodies.
- an anti-hnRNP antibody of this invention such as anti- hnRNP-F
- anti-idiotypic anti-hnRNP such as anti-hnRNP-F
- hnRNP such as hnRNP-F
- a test reagent that specifically binds to these proteins a number of different methods might be used.
- the sample, or a purified portion thereof is contacted with the agent under conditions that allow agent-antibody binding.
- the presence of the formed agent-antibody complex is then detected as an indication that the sample contains an anti-hnRNP antibody (such as anti- hnRNP-F).
- hnRNP-expressing cells such as hnRNP-H1 expressing cells for detecting anti-hnRNP-H1 antibodies
- Cell-based detection methods include techniques such as immunohistochemistry, immunofluorescence microscopy, or flow cytometric analysis.
- Non-cell based assays include immunosorbent assays (e.g. ELISA and RIA) and immunoprecipitation assays.
- the hnRNP of this invention e.g.
- hnRNP-H1 is immobilized on a substrate, a human serum sample is placed on the substrate under conditions that would allow binding of said anti-hnRNP antibodies (e.g. anti-hnRNP-H1 antibodies) to the immobilized hnRNP (e.g. hnRNP-H1).
- detectably labeled secondary antibody e.g. an anti- human immunoglobulin antibody if the biological sample was derived from a human subject
- detectable label e.g. an enzyme, fluorophore, or radioisotope
- antibodies contained within a biological sample are immobilized on a substrate, a detectably labeled hnRNP such as hnRNP-H1 is then placed on the substrate under conditions that would allow binding of the immobilized anti-hnRNP antibodies such as anti-hnRNP-H1 antibodies to said hnRNP such as hnRNP-H1.
- hnRNP-H1 antibodies a detectably labeled hnRNP such as hnRNP-H1 antibodies to said hnRNP such as hnRNP-H1.
- detectable label remaining on the substrate after washing indicates that the sample contained these anti-hnRNP antibodies, such as anti- hnRNP-H1 antibodies.
- the method of the invention can be carried out as qualitative or quantitative determination.
- the antibody concentrations which are above the so-called cutoff value are classified as positive.
- the cutoff value can be determined by calibrating the test system with positive and negative control samples. Alternatively, it is also possible to carry out a quantitative determination.
- test format is not in general critical. However, a test format can be preferred in which an immune complex comprising a hnRNP-antigen and the hnRNP autoantibody to be detected is bound to a solid phase. Alternatively, a competitive test format can be envisaged. Solid phases which can be employed are reaction vessels, microtiter plates, beads, biochips etc.
- the antigen can be immobilized on the solid phase by adsorptive interactions, covalent bonding or mediated by a high-affinity binding pair (streptavidin/biotin, hapten/anti-hapten antibody).
- the immobilized test reagent can be employed in a form which is already bound to a solid phase or else be immobilized only during the test.
- the method can be carried out as liquid test (e.g. in a reaction vessel) or else as dry test (e.g. on a test strip).
- the labeled test reagent may itself have a detectable or signal-emitting group (direct labeling) or be capable of binding to a detectable group (indirect labeling).
- the labeling group can be selected as desired from all labeling groups known from the prior art for immunological detection methods, for example from enzymes, metal particles or latex particles, and luminescent or fluorescent groups. It is particularly preferred for the labeling group to be selected from enzymes, e.g. peroxidase, ⁇ -galactosidase or alkaline phosphatase, and for the method to be carried out in the ELISA format.
- Dot blot assay Purified or recombinant hnRNP-F-antigen is spotted on a nitrocellulose or polyvinylidene difluoride (PVDF) membrane.
- the membrane strips are firstly blocked with blocking reagent. After a washing step to remove unbound proteins, they are incubated with diluted serum of the patient, a positive and a negative control serum. They are further washed with washing buffer and treated with alkaline phosphatase labeled protein A conjugate to bind the captured antibodies.
- the purified or recombinant hnRNP-F-antigen is separated on a one dimensional sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) prior to blotting on a membrane.
- SDS-PAGE sodium dodecyl sulfate polyacrylamide gel
- the membrane strip is blocked in blocking buffer (BSA or skim milk powder).
- BSA blocking buffer
- the membrane is subsequently treated with diluted serum of the patient, anti-human IgG conjugated with horseradish peroxidase (HRP) or a fluorescent dye and a substrate to visualize the bound antibodies. Intermittent washing steps will remove the unbound proteins.
- This Western blot assay can be used in combination with other proteins of different molecular weight loaded in the same lane on SDS-PAGE (cfr. line assay). This technique is labor intensive but permits to screen the sera simultaneously for the presence of different auto-antibodies. It's a qualitative method.
- An Enzyme Linked Immunosorbent Assay provides a quantitative in vitro assay for the detection of antibodies.
- Polystyrene microplate strips are coated with purified, biochemically characterized pure or recombinant hnRNP-F-antigen as solid phase. If the sample is positive, specific antibodies in the diluted serum sample attach to the antigens coupled to the solid phase.
- the attached antibodies are detected with peroxidase-labeled anti-human antibodies.
- the bound antibodies are visualized using a chromogen/substrate solution which is capable of promoting a color reaction. The intensity of the color produced is proportional to the concentration of antibodies in the serum sample and is measured using a spectrophotometer with filter settings of a suitable wavelength.
- a Fluoro Enzyme Immuno Assay provides a quantitative in vitro assay for the detection of antibodies.
- a carier e.g. polystyrene microplate strips
- purified, biochemically characterized pure or recombinant antigen e.g. hnRNP-F-antigen
- the attached antibodies are detected with an enzyme-labeled anti-human antibodies.
- the bound antibodies are visualized using a substrate solution which is capable of promoting a color reaction.
- the intensity of the color/fluorescence produced is proportional to the concentration of antibodies in the serum sample and is measured using a spectrophotometer with filter settings of a suitable wavelength.
- the fluorescence of the serum sample is than compared to a standard curve.
- Radio Immuno assays are immuno assays in which radioactive isotopes are used as labels for detection. These assays use gamma and beta counters for detection and are highly sensitive. The greatest disadvantage of radio immuno assays is that the amount of use and the kind of radioisotopes are limited by regulations and radioactive wastes are released in large amounts. Therefore, the RIA is becoming less popular as an immunoassay.
- Bead-based assays Human serum is treated with different sets of color-coded polystyrene beads, each bearing a different antigen (including hnRNP-F). Individual beads bearing interacting antibodies are detected by flow cytometry. The beads are aligned into single files as they enter a stream of sheath fluid and then enter a flow cell. Once the beads are in single file within the flow cell, each bead is individually interrogated for bead color (analyte) and assay signal strength (fluorescence intensity). This is a fast, reproducible and reliable but expensive technique. Only a limited number of antigens can be screened.
- Antigen array Several antigens, including hnRNP-F, are printed on nitrocellulose or superaldehyde coated slides. Printed microarray chips are then washed in wash buffer and probed with diluted patient's serum. Afterwards, fluorescently labeled anti-human IgG conjugate is added and the slides are washed again. The fluorescent signal is further quantified by scanning and image analysis software. These antigen arrays allow to simultaneously screen for the presence of an unlimited amount of autoantibodies.
- Anti-auto-hnRNP antibodies of the invention (such as anti-auto-hnRNP-F antibodies) for therapy
- Anti-autoimmune antibodies or inhibitor(s) of the present invention include polypeptides comprising the epitope of the antibody or biologically active fragment thereof, or polypeptide that is functional in conferring protection in the individual suffering from autoimmune disease, or functionally conserved fragments or amino acid variants thereof. Identification of the epitope is a matter of routine experimentation. Most typically, one would conduct systematic substitutional mutagenesis of the compound molecule while observing for reductions or elimination of cytoprotective or neutralizing activity. In any case, it will be appreciated that due to the size of many of the antibodies, most substitutions will have little effect on binding activity. The great majority of variants will possess at least some cytoprotective or neutralizing activity, particularly if the substitution is conservative. Conservative amino acid substitutions are substitutions from the same class, defined as acidic (Asp, Glu), hydroxy-like (Cys,
- Homologous antibody or polypeptide sequences generally will be greater than about 30 percent homologous on an identical amino acid basis, ignoring for the purposes of determining homology any insertions or deletions from the selected molecule in relation to its native sequence.
- the compounds discussed herein i.e. autoimmune inhibitors for administration to the patient with autoimmune disease and/or for removal, neutralization or inhibition of the autoimmunogen(s) by extracorporeal immunosorption in accordance with the present invention, also include glycosylation variants as well as unglycosylated forms of the agents, fusions of the agents with heterologous polypeptides, and biologically active fragments of the agents, again so long as the variants possess the requisite neutralizing or cytoprotective activity.
- treatments involving administration of an autoimmune inhibitor to a patient may be performed alone or in combination.
- Administered autoimmune inhibitor of the invention binds to, neutralizes and/or inhibits the molecule(s) associated with or causing the autoimmune response in the patient. More specifically, administration of the autoimmune inhibitor to a patient results in suppression of pathological humoral and adaptive immunity in the patient.
- treatment of a patient with the autoimmune inhibitor causes the humoral and adaptive immune response of the patient to be inhibited or neutralized over that which was, or would have been, present in the absence of treatment.
- a patient is in need of treatment with an autoimmune inhibitor, when the patient is suffering from an autoimmune disease or when the patient has produced autoantibodies.
- the autoimmune inhibitor antibody(ies) is also effective when immobilized on a solid support.
- solid supports include, but are not limited to, plastics such as polycarbonate, complex carbohydrates such as agarose and sepharose, and acrylic resins, such as polyacrylamide and latex beads.
- Techniques for coupling antibodies to such solid supports are well known in the art(Weir et a/., "Handbook of experimental Immunology” 4th Ed., Blackwell Scientific Publications, Oxford, England, Chap. 10 (1986); Jacoby et a/., Meth. Enzym. 34 Academic Press, N.Y.(1974)).
- autoantibody gene products may be generated which include proteins that represent functionally equivalent gene products.
- an equivalent hnRNP-F antibody gene product may contain deletions, including internal deletions, additions, including additions yielding fusion proteins, or substitutions of amino acid residues, but that result in a "silent" change, in that the change produces a functionally equivalent auto-hnRNP-F antibody gene product.
- Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved.
- nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.
- deletion or non-conservative alterations can be engineered to produce altered anti-hnRNP-F antibody gene products.
- Such alterations can, for example, alter one or more of the biological functions of the autoantibody gene product. Further, such alterations can be selected so as to generate autoantibody gene products that are better suited for expression, scale up, etc. in the host cells chosen. For example, cysteine residues can be deleted or substituted with another amino acid residue in order to eliminate disulfide bridges. This applies to any autoimmune hnRNP-F molecule and allelic variants thereof, that are identified in an individual.
- the autoantibody gene products, peptide fragments thereof and fusion proteins thereof, of the invention can be produced by recombinant DNA technology using techniques well known in the art. Methods that are well known to those skilled in the art can be used to construct expression vectors comprising auto- hnRNP-F antibody gene product coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. See, for example, the techniques described in Sambrook, et at., 1989, and Ausubel, et at., 1989.
- RNA capable of encoding auto-hnRNP-F antibody gene product sequences may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, ed., IRL Press, Oxford.
- host-expression vector systems may be utilized to express the autoantibodies, such as anti- hnRNP-F gene products.
- Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently purified, but also represent cells that may, when transformed or transfected with the appropriate nucleotide coding sequences, exhibit the anti- hnRNP-F gene product of the invention in situ.
- the efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner, er a/., 1987, Methods in Enzymol. 153, 516-544).
- a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g. glycosylation) and processing (e.g. cleavage) of protein products may be important for the function of the protein.
- Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells that possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used.
- Such mammalian host cells include but are not limited to CHO, JURKAT, Hep2, VERO, BHK, HeLa, COS, MDGK, 293, 3T3, and W138.
- a variety of methods can be employed for the diagnostic and prognostic evaluation autoimmune disorders such as Sjogren's syndrome and for the identification of subjects having a predisposition to such autoimmune disorders. Such methods may, for example, detect the presence of hnRNP (such as hnRNP- F) gene mutations, or the detection of either over- under- or no expression of hnRNP (such as hnRNP- F) protein, or mutants.
- hnRNP such as hnRNP- F
- Mutations at a number of different genetic loci may lead to phenotypes related to autoimmune disorder, structural and synaptic abnormalities.
- the treatment of patients suffering from such disorders will be designed to target the particular genetic loci comprising the mutation mediating the disorder.
- Genetic polymorphisms have been linked to differences in drug effectiveness.
- identification of alterations in hnRNP (such as hnRNP-F) molecules, such as, for example, gene or protein can be utilized to optimize therapeutic drug treatments.
- autoimmune related molecule such as, for example, hnRNP-F, expression levels, mutations, polymorphisms
- a microassay of for example, hnRNP-F nucleic acid sequences immobilized to a substrate or "gene chip" for detection of hnRNP-F molecules see, e.g. Cronin, ef a/., 1996, Human Mutation 7:244-255. Preferred methods are detailed in the examples which follow.
- hnRNP e.g. hnRNP-F
- hnRNP-F hnRNP-F gene expression assays "in situ", i.e. directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary.
- tissue sections fixed and/or frozen
- Antibodies directed against hnRNP such as hnRNP-F gene products may be used in vitro to determine, for example, the level of hnRNP (such as hnRNP-F) antibody gene expression achieved in cells genetically engineered to produce such a gene product.
- hnRNP such as hnRNP-F
- intracellular gene products such an assessment is done, preferably, using cell lysates or extracts. Such analysis will allow for a determination of the number of transformed cells necessary to achieve therapeutic efficacy in vivo, as well as optimization of the gene replacement protocol.
- the tissue or cell type to be analyzed will generally include those that are known, or suspected, to express the hnRNP gene (e.g. the hnRNP-F gene).
- the protein isolation methods employed herein may, for example, be such as those described in Harlow and Lane (1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.).
- the isolated cells can be derived from cell culture or from a patient.
- the analysis of cells taken from culture may be a necessary step in the assessment of cells to be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the hnRNP gene (e.g. the hnRNP-F gene).
- Preferred diagnostic methods for the detection of autoimmune molecules may involve, for example, immunoassays wherein the hnRNP-F gene products or conserved variants or peptide fragments are detected by their interaction with an anti-hnRNP-F gene product-specific antibody. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody coupled with light microscopic, flow cytometric, or fluorimetric detection.
- subject or “patient” refers to any human or animal mammals.
- autoimmune disease refers to a disease that result from an aberrant immune response of an organism against its own cells and tissues due to a failure of the organism to recognise its own constituent parts (down to the sub-molecular level) as “self.
- autoimmune disease is intended to further include autoimmune conditions, syndromes and the like.
- autoimmune diseases include, but are not limiting to, Sjogren syndrome, scleroderma, dermatomyositis, polymyositis, rheumatoid arthritis, mixed connective tissue disease, insulin-dependent diabetes mellitus, hemolytic anemias, rheumatic fever, thyroiditis, Crohn's disease, myasthenia gravis, glomerulonephritis, autoimmune hepatitis, multiple sclerosis, and systemic lupus erythematosus.
- an "antigen” as used herein refers to a structure of a macromolecule, typically protein (with or without polysaccharides) or made of proteic composition comprising one or more hapten(s) and/or comprising at least one epitope.
- An “autoantigen” as used herein refers to a human or animal protein present in the body, which elicits an immune response within the same human or animal body, which may in turn lead to a chain of events, including the synthesis of other autoantigens or autoantibodies.
- An “autoantibody” is an antibody (ab) produced by an autoimmune patient to one or more of his own constituents which are perceived to be antigenic. For example, in SLE autoantibodies are produced to DNA, while in many other types of AD autoantibodies are produced to target cells.
- autoimmune diseases including, e.g., rheumatoid arthritis, insulin-dependent diabetes mellitus, hemolytic anemias, rheumatic fever, thyroiditis, Crohn's disease, myasthenia gravis, glomerulonephritis, autoimmune hepatitis, multiple sclerosis, systemic lupus erythematosus and others, are in need of treatment in accordance with the present invention.
- Treatment of patients suffering from these diseases by administration of autoimmune inhibitor and/or removal of compound(s) by extracorporeal immunosorption in accordance with the present invention will alleviate the clinical manifestations of the disease and/or minimize or prevent further deterioration or worsening of the patient's condition.
- Treatment of a patient at an early stage of an autoimmune disease including, e.g., rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, or others, will minimize or eliminate deterioration of the disease state into a more serious condition.
- an autoimmune disease including, e.g., rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus, or others, will minimize or eliminate deterioration of the disease state into a more serious condition.
- epitope refers to one or several portions (which may define a conformational epitope) of an antigenic protein which is/are specifically recognised and bound by an antibody or a portion thereof (Fab', FabZ, etc.) or a receptor presented at the cell surface of a B or T cell lymphocyte, and which is able, by
- An epitope can comprise as few as 3 amino acids in a spatial conformation which is unique to the epitope. Generally an epitope consists of at least 6 such amino acids, and more usually at least 8-10 such amino acids.
- Methods for determining the amino acids which make up an epitope include x-ray crystallography, 2-dimensional nuclear magnetic resonance, and epitope mapping e.g. the Pepscan method described by H. Mario Geysen et al. 1984. Proc. Natl. Acad. Sci. U.S.A. 81 :3998-4002; PCT Publication No. WO 84/03564; and PCT Publication No. WO 84/03506. It is well known to a person skilled in the art that antibodies which recognize and bind an epitope can be monoclonal or polyclonal.
- the phrase "specifically (or selectively) binds" to an antibody when referring to a protein or peptide, refers to a binding reaction that is determinative of the presence of the protein in a heterogeneous population of proteins and other biologies.
- the specified antibodies bind to a particular protein at least two times the background and do not substantially bind in a significant amount to other proteins present in the sample.
- Specific binding to an antibody under such conditions may require an antibody that is selected for its specificity for a particular protein.
- polyclonal antibodies raised to marker "X" from specific species such as rat, mouse, or human can be selected to obtain only those polyclonal antibodies that are specifically immunoreactive with marker "X” and not with other proteins, except for polymorphic variants and alleles of marker "X". This selection may be achieved by subtracting out antibodies that cross-react with marker "X" molecules from other species.
- a variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein.
- solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory Manual (1988), for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).
- a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 to 100 times background.
- Immunoassay is an assay that uses an antibody to specifically bind an antigen (e.g. a marker). The immunoassay is characterized by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the antigen.
- Diagnostic means identifying the presence or nature of a pathologic condition. Diagnostic methods differ in their sensitivity and specificity.
- the "sensitivity” of a diagnostic assay is the percentage of diseased individuals who test positive (percent of "true positives”). Diseased individuals not detected by the assay are “false negatives.” Subjects who are not diseased and who test negative in the assay, are termed “true negatives.”
- the "specificity” of a diagnostic assay is 1 (or 100 when indicated as percentage) minus the (percentage) false positive rate, where the "false positive” rate is defined as the proportion of those without the disease who test positive.
- nucleic acid delivery vector may be provided as naked nucleic acids or in a delivery vehicle associated with one or more molecules for facilitating entry of a nucleic acid into a cell.
- Suitable delivery vehicles include, but are not limited to: liposomal formulations, polypeptides; polysaccharides; lipopolysaccharides, viral formulations (e.g. including viruses, viral particles, artificial viral envelopes and the like), cell delivery vehicles, and the like.
- liposomal formulations polypeptides
- polysaccharides polysaccharides
- lipopolysaccharides lipopolysaccharides
- viral formulations e.g. including viruses, viral particles, artificial viral envelopes and the like
- cell delivery vehicles e.g. including viruses, viral particles, artificial viral envelopes and the like
- hnRNPs as new target of auto-antibodies in patients with autoimmune diseaes such as Sjogren's syndrome.
- Antibodies to hnRNP-AI , -B1 , -C1 , -El , -F , -H1 , -I, -K, and -P2 were all significantly detected in patients with primary Sjogren's syndrome (see Table 1 and 2 in Example 2).
- Certain combinations of these hnRNP-markers are extremely relevant for the diagnosis of autoimmune diseaes such as Sjogren's syndrome. These combinations comprise the ones depicted in grey background color in Table 4.
- Preferred combinations of hnRNP-markers to detect Sjogren's syndrome are 'hnRNP-F and -H1 ', 'hnRNP-E1 , and -F', 'hnRNP-E1 , -F, and -B1', 'hnRNP-E1 , -F, -H1 , and -B1 ' 'hnRNP-A1 , -B1 , -F, and -H1 ⁇ 'hnRNP-E1 , -F, and -H1', and 'hnRNP-A1 , -B1 , -E1 , -F, and -HT.
- a method comprising the analysis of this combination of markers (hnRNP-E1 , -F, and -H1 ) can be used to diagnose patients for Sjogren's syndrome, mixed connective tissue disease (MCTD), dermatomyositis (DM) and SLE.
- MCTD mixed connective tissue disease
- DM dermatomyositis
- a method comprising the analysis of this combination of markers (hnRNP-B1 and -A1) can be used to diagnose patients for SSc.
- single antibodies to hnRNP-A1 , -B1 , -E1 , -F, and -H1 are detected in more than 37% of the
- fragments of hnRNP-H1 were analysed as markers for several autoimmuun diseases.
- fragments 1 , 2, 3 and 4 of hnRNP-H1 are useful as a marker for Sjogren's syndrome.
- Fragments 2, 3 and 4 show the highest positive values for Sjogren's syndrome in Table 1 indicating that most antibodies to hnRNP-H1 in Sjogren's syndrome patients recognize these fragments.
- fragments 2 and 4 of hnRNP-H1 are extremely homologue to certain regions (the RRM1 en 2 regions respectively) in hnRNP-F (as shown in Fig 2), indicating that these hnRNP-H1 and -F markers and more particularly the aforementioned regions/fragments or amino acid sequences that are higly homologues to these regions/fragments (preferably more than 80, 85, 90, or 95 % homologues to the aforementioned
- hnRNP-B1 The high reactivity to hnRNP-B1 , hnRNP-E1 , and hnRNP-F in Sjogren's syndrome was confirmed by ELISA.
- ELISA did not reveal significantly higher reactivity for hnRNP-H1 in Sjogren's syndrome than in controls. This might be related to differences in conformation of the protein between ELISA and Western blotting.
- Antibodies to hnRNP B1 were found in Sjogren's syndrome and in several other connective tissue diseases including mixed connective tissue disease and systemic lupus erythematosus.
- ELISA analysis further confirmed the notion that the simultaneous presence of antibodies to several hnRNPs was strongly associated with connective tissue disease in general and Sjogren's syndrome in particular. For example, reactivity to at least 2 of the 4 tested antigens was found in 1.1 % of controls, in 16% of patients with systemic lupus erythematosus, and in 18% of patients with Sjogren's syndrome. Reactivity to at least 3 of the 4 antigens was found in none of the controls and in 15% of patients with Sjogren's syndrome.
- ELISA analyses were done on diagnostic samples (i.e. samples that were obtained at the time of diagnosis).
- diagnostic samples i.e. samples that were obtained at the time of diagnosis.
- 19 tested positive for at least 1 of the four antigens tested hnRNP-B1 , -E1 , -F and -H1 .
- Two of these patients were negative for anti-SSA or anti-SSB antibodies.
- diagnostic samples from patients with systemic lupus erythematosus and with systemic sclerosis that were negative for the classical antibodies to extractable nuclear antigens and to dsDNA but positive for antibodies to hnRNPs.
- hnRNP-A1 and -B1 showed 60.5% identity. Both proteins have two moderate homologous RRM's and a glycine rich region. HnRNP-H1 and -F have an identity of 78%. Even though the proteins are closely sequence-related, they exhibit differences, especially in their COOH terminus, where hnRNP-F is shorter and contains a deletion
- hnRNP-F and -H1 are highly related immunologically.
- hnRNP's are target antigens in Sjogren's syndrome.
- the combined presence of antibodies to several hnRNP's was strongly associated with connective tissue disease in general and Sjogren's syndrome in particular.
- hnRNP-E1 and hnRNP-F new targets of autoantibodies in patients with an autoimmune diseases, in particular Sjogren's syndrome. Therefore, we identified these antibodies and combinations of these antibodies as valuable diagnostic markers in autoimmune diseases, in particular Sjogren's syndrome.
- the second group of samples consisted of diagnostic samples (i.e. samples obtained at the time of diagnosis).
- CFS chronic fatigue syndrome
- CVS chronic fatigue syndrome
- hnRNP A1 , H1 , F and I obtained from Douglas Black, Howard Hughes Medical Institute, LA
- hnRNP P2 obtained from Takumi, Osaka Bioscience, Institute Japan
- hnRNP E1 en K obtained from Kent Duncan, University of Berlin
- hnRNP G obtained from Chiou, National Chung Hsing University, Taiwan
- hnRNP C1 obtained from Chang, National Taiwan University, Taiwan was used.
- cDNA of hnRNP B1 was constructed by isolation of RNA out of HeLa cells by means of the RNeasy mini kit (Qiagen). RNA was converted to cDNA using the RevertAid H Minus First Strand synthesis kit (Fermentas).
- PCR product was first cloned in the plasmid pDONR-221 using a BP clonase reaction and subsequently in the expression plasmid pDEST-17 by a LR clonase reaction.
- the gene was extended with a hexahistidine (6x His) coding sequence at its 5' end upon cloning in the pDEST-17 vector. Thereafter, expression was induced in E.
- Immobilizer amino plates were coated 2 hours at room temperature with 100 ⁇ per well with 1 pg/ml hnRNP B1 , E1 , F or M . After washing the plates four times with 1x PBS-Tween 20 (0.05%), 50 ⁇ of serum sample was added (dilution 1:50 in PBS). The plates were incubated at room temperature for 30 min. Thereafter, 100 ⁇ of horseradish peroxidase-conjugated goat anti-human IgG (diluted 1 :5000 in PBS) was added to each well and the plates were incubated at room temperature for 30 min. Between each step, the plates were washed four times with 1x PBS-Tween 20 (0.05%).
- the color reaction was developed using 3,3',5,5'-tetramethylbenzidine as substrate (100 ⁇ per well). The wells were incubated in the dark at room temperature for 15 min. This enzymatic coloration was stopped by addition of 100 ⁇ 0.5M H2S04 and the optical density was measured at 450 nm. A positive sample was used as standard. To this standard (six bi-fold serial dilutions starting from 1/50 to 1/1600), 100 arbitrary units were assigned. In each run, a positive and a negative control were included. The optical density of the samples was measured. Arbitrary units were calculated based on a standard curve. The coefficient of variation of the positive control (for all antigens) was ⁇ 13% over 12 runs.
- hnRNP-H1 was described as a newly recognized target of autoantibodies. These antibodies were mainly found in patients with Sjogren's syndrome, but were also present in patients with other autoimmune-mediated diseases (WO2009055880). Characterization of reactive epitopes allows us to study the mechanism of epitope spreading and to simplify the design of detection methods for the fast detection of autoantibodies. In addition we want to examine whether positivity against a specific epitope can be linked with a characteristic pathology or clinical phenotype. Previous epitope mapping studies proved that with some hnRNPs, like hnRNP A, B en D, the prominent antibody binding sites are localized at the RNA Recognition Motifs (RRMs).
- RRMs RNA Recognition Motifs
- HnRNP-H1 was split up in five separate fragments (1-5) and these were expressed as recombinant oligopeptides.
- the choice of the restriction sites was made based on the location of the RRMs and the secondary structure of the hnRNP-H1 protein.
- the five different fragments that are generated (and His-tagged) in this study are:
- Fragments 1 to 4 are used to study the prevalence of antibodies recognizing these fragments in patients with autoimmune connective tissue disorders and the results are shown in Fig. 3 to 6. Fragment 3 and 4 appear to be the antigens with the largest antibody binding capacity. No antibodies to fragment 5 could be detected.
- the objective of this study was to evaluate the value of antibodies against different hnRNP proteins in patients with a connective tissue disease and in diseased controls (DC).
- a total of 404 sera from patients with different systemic rheumatic diseases was tested for reactivity to 10 recombinant human hnRNP proteins (with numbers from UniProtKB/Swiss-Prot Database: hnRNP-A1 (P09651), -B1 (P22626), - C1(P07910), -E1(Q15365), -F (P52597), -Gi (P38159), -H1 (P31943), -I (Q9BUQ0), -K (P61978) and -P2 (P35637)).
- Recombinant proteins were produced according to the Gateway Cloning System. Constructs were transformed in E. coli BL21AI competent cells, and expressed as His-tagged fusion proteins. The identity of the proteins was confirmed by MALDI-TOF/TOF. Reactivity of serumantibodies to hnRNPs was tested by Gel electrophoresis and Western blotting. Statistical significance was evaluated by Mann- Whitney and Fisher exact testing. The results that show the prevalence of antibodies recognizing these 10 different hnRNPs in patients with autoimmune connective tissue disorders are depicted in Fig. 7 to 16. The results of this study are summarized in the next tables.
- Table 1 Summary of prevalences of antibodies to the hnRNP proteins and fragments 1 , 2, 3 and 4 of hnRNP-H1 in different systemic rheumatic diseases. Values are percentages with a cutoff set at 97,5 % specificity in CVS, the disease control (DC).
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- A, B, C, E, F, Gi, H, I, K, P, and 1 , 2, 3, and 4 stand for hnRNP-A1 , -B1 , -C1 , -E1 , -F, -Gi, -H1 , -I, -K, -P2, and fragment 1 , 2, 3 and 4 of hnRNP-H1 respectively.
- Table 2 Summary of the fisher exact statistical analyses of all specific Abs tested. Statistically significant differences in prevalence were assessed by Fisher exact test for the comparison between the diseased and the control (CVS) group. The significant values (p ⁇ 0.05) are indicated in grey background.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- A, B, C, E, F, Gi, H, I, K, P, and 1 , 2, 3, and 4 stand for hnRNP-A1 , -B1 , -C1 , - E1 , -F, -Gi, -H1 , -I, -K, -P2, and fragment 1 , 2, 3 and 4 of hnRNP-H1 respectively. P values are not corrected for multiple comparisons.
- Table 3 This table shows the results for Mann-Whitney statistical analysis between each diseased group and the control group (CVS). The significant values (p ⁇ 0.05) are indicated in grey background.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CVS chronic fatigue syndrome.
- A, B, C, E, F, Gi, H, I, K, P, and 1 , 2, 3, and 4 stand for hnRNP-A1 , -B1 , -C1, - E1 , -F, -Gi, -H1 , -I, -K, -P2, and fragment 1 , 2, 3 and 4 of hnRNP-H1 respectively. P values are not corrected for multiple comparisons.
- Table 4 Summary of the simultaneous presence of Abs to different hnRNPs used in this study. The significant values (p ⁇ 0.05, Fisher-exact, see Table 5) are indicated in grey background.
- SSp primary Sjogren's syndrome
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CFS chronic fatigue syndrome.
- A, B, E, F, H, I, and K stand for hnRNP-A1 , -B1 , -E1 , -F, -H1 , -I, and -K respectively.
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SSc scleroderma
- DM dermatomyositis
- PM polymyositis
- RA rheumatoid arthritis
- CFS CFS
- A, B, E, F, H, I, and K stand for hnRNP-A1, -B1, -E1, -F, -H1, -I, and -K respectively.
- the simultaneous presence of antibodies to hnRNP A1 and B1 was associated with DM, Ssc and SSp, while the simultaneous presence of antibodies to hnRNP H1 and F was associated with DM and SSp.
- the simultaneous presence of antibodies to hnRNP B1 and K was associated with DM and SSp, and the simultaneous presence of antibodies to hnRNP E1, F and H1 was associated with DM, MCTD and SSp.
- Patients with DM have also combined presence to several hnRNPs. More than 20% has combined Abs to A1 and B1, and 17% has Abs to F and H1, and to B1 and K.
- Figures 18 and 9 show the reactivity to a selection of 8 hnRNP's in controls, in patients with systemic sclerosis, in patients with Sjogren's syndrome, and in patients with a connective tissue disease other than systemic sclerosis or Sjogren's syndrome.
- the highest reactivity was found in Sjogren's syndrome.
- the reactivity was statistically significantly higher in Sjogren's syndrome than controls , systemic sclerosis, and connective tissue diseases other than Sjogren's syndrome (p ⁇ 0.05 Kruskall Wallis with Bonferroni correction).
- the reactivity in connective tissue diseases other than Sjogren's syndrome and systemic sclerosis was higher than the reactivity in controls and in systemic sclerosis for all antigens except hnRNP Gi and hnRNP K.
- Antibodies to hnRNP A1 , hnRNP B1 , and hnRNP P2 were significantly more prevalent in mixed connective tissue disease than in controls, and antibodies to hnRNP A1 , hnRNP B1 , and hnRNP F were significantly more prevalent in dermatomyositis than in controls. Reactivity to at least 1 of the 10 antigens was found in 19% of controls and in 45% of dermatomyositis, 49% of rheumatoid arthritis, 38% of systemic lupus erythematosus, 53% of mixed connective tissue disease, and 73% of Sjogren's syndrome.
- Reactivity to at least 3 antigens was found in 2% of controls, 14% of systemic sclerosis, 27% of dermatomyositis, 14% of systemic lupus erythematosus, 26% of mixed connective tissue disease, and 48% of Sjogren's syndrome. Reactivity to at least 5 antigens was found in none of the controls, 7% of systemic sclerosis, 14% of dermatomyositis, 7% of systemic lupus erythematosus, 16% of mixed connective tissue disease, and 32% of Sjogren's syndrome (Table 7).
- Reactivity to at least 1 of the 4 tested antigens was found in 11% of the controls, 35% of rheumatoid arthritis, 47% of systemic lupus erythematosus, 64% of mixed connective tissue disease, and 56% of Sjogren's syndrome.
- Reactivity to at least 2 of the 4 tested antigens was found in 1.1% of controls, in 16% of patients with systemic lupus erythematosus, and in 18% of patients with Sjogren's syndrome.
- Reactivity to at least 3 of the 4 antigens was found in none of the controls and in 15% of patients with Sjogren's syndrome.
- Table 8 Prevalence of antibodies measured by ELISA to hnRNP B1, E1, F, and H1 in controls and different connective tissue diseases [systemic sclerosis (SSc), polymyositis (PM), dermatomyositis (DM), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), Sjogren's syndrome (SS)].
- SSc systemic sclerosis
- PM polymyositis
- DM dermatomyositis
- RA rheumatoid arthritis
- SLE systemic lupus erythematosus
- MCTD mixed connective tissue disease
- SS Sjogren's syndrome
- MCTD mixed connective tissue disease
- SSp Sjogren's syndrome
- CFS controls
- BD blood donors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne des nouveaux procédés permettant de diagnostiquer plusieurs maladies auto-immunes. Plus particulièrement, la présente invention concerne des procédés et des compositions permettant de détecter des auto-anticorps d'anti-ribonucléoprotéines nucléaires hétérogènes pour diagnostiquer ces maladies auto-immunes. Plus particulièrement, la présente invention concerne des procédés et des compositions permettant de détecter des anti-ribonucléoprotéines nucléaires hétérogènes E, -F, -H, -A1, et -B1, y compris toutes les combinaisons de celles-ci, pour diagnostiquer des maladies auto-immunes, plus particulièrement pour diagnostiquer le syndrome de Sjögren, la connectivité mixte et la dermatomyosite.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10788225A EP2480894A2 (fr) | 2009-09-02 | 2010-09-02 | Procédés permettant de diagnostiquer des maladies auto-immunes |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0915332.1 | 2009-09-02 | ||
| GB0915332A GB0915332D0 (en) | 2009-09-02 | 2009-09-02 | New methods for diagnosing autoimmune diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2011026200A2 true WO2011026200A2 (fr) | 2011-03-10 |
| WO2011026200A3 WO2011026200A3 (fr) | 2011-09-29 |
| WO2011026200A9 WO2011026200A9 (fr) | 2012-08-02 |
Family
ID=41203089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/BE2010/000061 WO2011026200A2 (fr) | 2009-09-02 | 2010-09-02 | Nouveaux procédés permettant de diagnostiquer des maladies auto-immunes |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2480894A2 (fr) |
| GB (1) | GB0915332D0 (fr) |
| WO (1) | WO2011026200A2 (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059606A1 (fr) * | 2011-10-21 | 2013-04-25 | Tufts Medical Center, Inc. | Composés et méthodes pour le traitement d'une maladie musculaire, et procédés de dépistage associés |
| EP3472201A4 (fr) * | 2016-06-20 | 2020-05-13 | Healthtell Inc. | Procédés pour le diagnostic différentiel de maladies auto-immunes |
| US11371990B2 (en) | 2016-11-11 | 2022-06-28 | Cowper Sciences Inc. | Methods for identifying candidate biomarkers |
| WO2023144421A1 (fr) * | 2022-01-31 | 2023-08-03 | Katholieke Universiteit Leuven | Auto-antigènes de la sclérose systémique |
| US11774446B2 (en) | 2016-06-20 | 2023-10-03 | Cowper Sciences Inc. | Methods for diagnosis and treatment of autoimmune diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984003506A1 (fr) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Sequences d'acides amines antigeniquement actives |
| WO1984003564A1 (fr) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Procede de determination de sequences d'acides amines antigeniquement actives |
| WO2009055880A2 (fr) | 2007-10-29 | 2009-05-07 | Katholieke Universiteit Leuven | Nouveau procédé de diagnostic du syndrome de sjögren |
-
2009
- 2009-09-02 GB GB0915332A patent/GB0915332D0/en not_active Ceased
-
2010
- 2010-09-02 WO PCT/BE2010/000061 patent/WO2011026200A2/fr active Application Filing
- 2010-09-02 EP EP10788225A patent/EP2480894A2/fr not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984003506A1 (fr) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Sequences d'acides amines antigeniquement actives |
| WO1984003564A1 (fr) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Procede de determination de sequences d'acides amines antigeniquement actives |
| WO2009055880A2 (fr) | 2007-10-29 | 2009-05-07 | Katholieke Universiteit Leuven | Nouveau procédé de diagnostic du syndrome de sjögren |
Non-Patent Citations (10)
| Title |
|---|
| "Oligonucleotide Synthesis", 1984, IRL PRESS |
| BITTNER ET AL., METHODS IN ENZYMOL., vol. 153, 1987, pages 516 - 544 |
| CAPORALI R ET AL., AUTOIMMUNITY, vol. 38, 2005, pages 25 - 32 |
| CRONIN ET AL., HUMAN MUTATION, vol. 7, 1996, pages 244 - 255 |
| H. MARIO GEYSEN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 81, 1984, pages 3998 - 4002 |
| HARIOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS |
| JACOBY ET AL.: "Meth. Enzym.", vol. 34, 1974, ACADEMIC PRESS |
| KOVACS L ET AL., RHEUMATOLOGY, vol. 44, 2005, pages 1021 - 5 |
| NUOVO, G. J.: "PCR In Situ Hybridization: Protocols And Applications", 1992, RAVEN PRESS |
| WEIR ET AL.: "Handbook of experimental Immunology", 1986, BLACKWELL SCIENTIFIC PUBLICATIONS |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059606A1 (fr) * | 2011-10-21 | 2013-04-25 | Tufts Medical Center, Inc. | Composés et méthodes pour le traitement d'une maladie musculaire, et procédés de dépistage associés |
| US9662314B2 (en) | 2011-10-21 | 2017-05-30 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
| EP3472201A4 (fr) * | 2016-06-20 | 2020-05-13 | Healthtell Inc. | Procédés pour le diagnostic différentiel de maladies auto-immunes |
| US11747334B2 (en) | 2016-06-20 | 2023-09-05 | Cowper Sciences Inc. | Methods for differential diagnosis of autoimmune diseases |
| US11774446B2 (en) | 2016-06-20 | 2023-10-03 | Cowper Sciences Inc. | Methods for diagnosis and treatment of autoimmune diseases |
| US11371990B2 (en) | 2016-11-11 | 2022-06-28 | Cowper Sciences Inc. | Methods for identifying candidate biomarkers |
| WO2023144421A1 (fr) * | 2022-01-31 | 2023-08-03 | Katholieke Universiteit Leuven | Auto-antigènes de la sclérose systémique |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011026200A9 (fr) | 2012-08-02 |
| EP2480894A2 (fr) | 2012-08-01 |
| WO2011026200A3 (fr) | 2011-09-29 |
| GB0915332D0 (en) | 2009-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10670597B2 (en) | Methods and kits for monitoring membranous nephropathy | |
| AU2007320051B2 (en) | Methods and assays for detecting GP73-specific autoantibodies | |
| Horn et al. | Profiling humoral autoimmune repertoire of dilated cardiomyopathy (DCM) patients and development of a disease‐associated protein chip | |
| JP5998318B2 (ja) | 新規血管炎の検査方法および検査用試薬 | |
| US20120046181A1 (en) | Biomarkers for the Diagnosis of Renal Allograft and Kidney Status | |
| WO2011026200A2 (fr) | Nouveaux procédés permettant de diagnostiquer des maladies auto-immunes | |
| Locht et al. | Diagnostic and prognostic significance of measuring antibodies to alpha-fodrin compared to anti-Ro-52, anti-Ro-60, and anti-La in primary Sjögren's syndrome. | |
| JPWO2008001944A1 (ja) | 自己抗体検出用試薬及び自己免疫疾患の診断キット | |
| US20150133322A1 (en) | Method for the diagnosis of early rheumatoid arthritis | |
| Marnetto et al. | Western blot analysis for the detection of serum antibodies recognizing linear Aquaporin-4 epitopes in patients with Neuromyelitis Optica | |
| CN108948153B (zh) | 一种瓜氨酸修饰肽抗原组合及其应用 | |
| EP2380027B1 (fr) | Prédiction de diagnostic de l'arthrite rhumatoïde et lupus érythémateux systémique | |
| EP2668502B1 (fr) | Méthodes et moyens pour diagnostiquer la vasculite | |
| KR20020021813A (ko) | 이성질화된/임의로 반전된 에피토프에 대한 특이성자가면역 반응: 자가면역 질환 진단의 응용 | |
| EP2235540A2 (fr) | Nouveau procédé de diagnostic du syndrome de sjögren | |
| WO2019081692A1 (fr) | Procédé et moyens de diagnostic de l'hépatite auto-immune au moyen de marqueurs d'auto-anticorps | |
| EP2877852B1 (fr) | Microréseau de protéines permettant de caractériser la spécificité des immunoglobulines monoclonales de patients atteints d'une gammapathie monoclonale de signification indéterminée (mgus) ou d'un myélome | |
| KR102415209B1 (ko) | Kras 자가항체를 이용한 쇼그렌 증후군 진단방법 | |
| JP7523129B2 (ja) | ヘリコバクター・ピロリ菌株の同定方法、および同定用キット | |
| WO2013008930A1 (fr) | Méthode d'inspection pour le diagnostic de la dermatomyosite | |
| US20040180385A1 (en) | Method of diagnosing systemic lupus erythematosus | |
| WO2023275235A1 (fr) | Procédé et moyens de diagnostic de spondylarthrite | |
| JP2023502198A (ja) | 診断及び処置のための抗原ニューロン特異的エノラーゼペプチド | |
| Fritzler et al. | International Multicenter Evaluation of | |
| JP2012224594A (ja) | 環状シトルリン化グルコース−６−リン酸イソメラーゼペプチドおよび関節リウマチ症診断方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10788225 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2010788225 Country of ref document: EP |